JP2013230152A - Treatment and prevention of viral infection or improvement in treatment and prevention of viral infection - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide ligands capable of neutralizing hepatitis C virus (HCV), various amino acid residue-containing and/or nucleotide-containing compositions for eliciting antibodies against HCV, methods for preventing and/or treating HCV infection, and assay apparatus and methods for detecting HCV.SOLUTION: Disclosed is a polynucleotide encoding a polypeptide including an antibody binding site, the polypeptide being able to bind to HCV E2 samples representative of each of HCV genotypes 1-6, as well as polypeptides having such properties and a method for using such polypeptides in detecting and treating HCV infection.

Description

The present invention relates to a ligand capable of neutralizing hepatitis C virus (HCV), various amino acid residue-containing and / or nucleotide-containing compositions for inducing antibodies against HCV,
The present invention relates to a method for preventing and / or treating HCV infection, and an assay device and method for detecting HCV.

HCV is a positive-strand RNA virus that belongs to the Flaviviridae family. It is a major cause of non-A non-B viral hepatitis. About 200 million people have been infected with HCV so far, and current estimates suggest that 3 million people are newly infected each year (Reference 3). About 80% of infected people cannot eliminate the virus. Chronic infections result, often leading to severe chronic liver disease, cirrhosis and hepatocellular carcinoma (Refs. 2, 45). Current treatments for chronic infections are ineffective and the development of preventive and therapeutic vaccines is urgent.

Due to the error-prone nature of RNA-dependent RNA polymerase and the high replication rate in vivo (refs. 34, 50), HCV exhibits a high degree of genetic variability. HCV can be classified into six genetically distinct genotypes and can be further subdivided into at least 70 subtypes that differ by about 30% and 15%, respectively, at the nucleotide level (refs. 64, 66). An important challenge for vaccine development is identifying protective epitopes that are conserved in most of the viral genotypes and subtypes. This problem is further exacerbated by the fact that the envelope protein, the natural target for the neutralization response, is the two most variable proteins (Ref. 10).

Envelope proteins, E1 and E2, play a role in cell binding and invasion (Refs. 4, 8, 17, 55, 61). They have an N-terminal extracellular domain and a C-terminal hydrophobic membrane anchor (refs. 12, 23, 24) and N-linked glycosylation (refs. 22, 25,
35, 47, 67) It is a transmembrane protein. In vitro expression experiments show that E1 and E2
Proteins have been shown to form non-covalent heterodimers, which have been proposed to be functional complexes on the surface of the virus (refs. 14, 15, 18, 24). In addition, the exact mechanism of virus entry is unknown because there is no efficient culture system. Invasion into isolated primary hepatocytes and cell lines requires interaction with cell surface receptor CD81 and scavenger receptor class B1 type (SR-B1) (refs. 6, 7, 20, 6
3,71) are on the rise, but these receptors alone are not sufficient to allow viral entry.

Current evidence suggests that cellular immunity is crucial for the elimination and control of viral replication in acute infections (refs. 36, 72). However, surrogate models of infection such as animal infections and cell and receptor binding assays have highlighted the potential role of antibodies in both acute and chronic infections (refs. 5, 26, 27, 40, 59, 61, 62, 68, 73,
74). Of course, neutralizing antibodies recognize both linear and steric epitopes.
The majority of antibodies that exhibit a broad neutralizing capacity are directed to steric epitopes within E2 (Refs. 1, 9, 37, 38, 40). Induction of antibodies that recognize conserved steric epitopes is crucial for vaccine design, but the variable region appears to be immunodominant (ref. 59), which can prove to be difficult High nature. One such immunodominant linear epitope is present in the first hypervariable region of E2 (HVR1) (ref. 73). Although the use of conserved HVR1 mimotopes has been proposed to overcome limited specificity problems (11, 60, 75), it is still unclear whether this approach will be successful. We and other authors have described that the region immediately downstream of HVR1 contains many epitopes (refs. 16, 29, 32, 52, 54, 69). Residues 412-4
1 epitope defined by monoclonal antibody AP33
Inhibits the interaction between 81 and a series of presentations of E2, including soluble E2, E1E2, and virus-like particles (reference 52).

AP33 can block CD81 binding, but if this correlates directly with neutralizing ability, and if so, it is a fundamental property for any promising therapeutic antibody, the diverse nature of HCV Whether to neutralize a series of genetic variants is unknown. In addition, it is unclear whether other linear epitopes downstream of HVR1 may be important in the development of antibody-based vaccines. We (refs. 6, 8) and other authors (ref. 71) have recently developed a retroviral pseudoparticle (pp) assay in which the infectivity of retroviral particles is conferred by the HCV E1E2 envelope protein. This assay can also be used to measure the neutralizing capacity of antibodies and serum (Refs. 5, 44).
. We herein describe E1E2 representing genotypes 1 to 6 for measuring the cross-neutralizing ability of AP33 antibodies and polyclonal antisera recognizing AP33 epitopes and epitopes located in the region adjacent to HVR1. The use of HCV _pp reconstituted with clones is described.

The inventors have surprisingly found that the previously mentioned monoclonal antibody called AP33 binds to each of the six known genotypes 1-6 of HCV and can neutralize them. . Hybridomas that secrete AP33 monoclonal antibodies were developed under the European Convention of Cell Cultures (ECA) under the Budapest Treaty.
CC, CAMR Porton Down, Salisbury, Wiltshire
SP4 OJG UK; Deposit date 27th January 2006, Accession number 051221
01). Thus, the epitope targeted by AP33 is HCV
It is inferred to be cross-reactive with all of genotypes 1 to 6 of this gene, suggesting AP33 as a target for anti-HCV ligands and as an immunogen for raising anti-HCV antibodies.

According to the first aspect of the present invention, therefore, in the manufacture of a composition for the prevention or treatment of infection by each of HCV genotypes 1-6, the epitope of HCV E2 polypeptide defined by monoclonal antibody AP33 Use of a ligand capable of binding is provided.

In this context, “defined by” means that the epitope is a ligand of the invention and A
Meaning that P33 is the same epitope bound by monoclonal antibody AP33 so that it can compete for binding to that epitope.

Preferably, the ligand comprises the sequence _{X 1 LX 2 NX 3 X 4} GX 5 WX 6 X 7 ( wherein, X ₁ ~ ₇ are any amino acid at a) capable of binding to a polypeptide epitope with.

In a preferred embodiment, X ₁ is selected from the group consisting of S, E, Q, H, P and L.

In a preferred embodiment, X ₂ is selected from the group consisting of V, I, A, R and F.

In a preferred embodiment, X ₃ is selected from the group consisting of S, T, H, L and A.

In a preferred embodiment, X ₄ is selected from the group consisting of N, Q and G.

In a preferred embodiment, X ₅ is selected from the group consisting of S, K and T.

In preferred embodiments, X ₆ is selected from the group consisting of H, R, and Q.

In a preferred embodiment, X ₇ is selected from the group consisting of I, L, F or P.

Conveniently, the polypeptide epitope is QLINTNGSWHI, QLVNTNGS
WHI, QLINSNGSWHI, SLINTNGSWHI, ELINTNGSWHI,
Selected from the group consisting of HLANHQGKWRL, PLFNANGTWQF and ELRNLGGTWRP.

The ligand is preferably an immunoglobulin. As used herein, the term “immunoglobulin” includes the immunoglobulin superfamily members described below. Preferably, the immunoglobulin is an antibody. “Antibodies” are Fab, F (ab ′) ₂ , Fv,
Includes antibody fragments such as scFv and single domain antibody (dAb) molecules.

Preferably, the immunoglobulin comprises one or more CDRs derived from monoclonal antibody AP33 as shown in FIG. The CDR is conveniently
(A) RASESVDGYGNSFLH, LASNNLNS, QQNNVDPWT, GD
An array consisting of SITSGYWN, YISSYSGSTY or ITTTTYAMDY,
(B) a sequence having 1, 2 or 3 amino acid additions, substitutions or deletions from the sequence shown in (a), and (c) the sequence shown in (a) when the CDR is present in an immunoglobulin; Selected from the group consisting of structurally similar sequences.

Structural similarity in this case refers to the similarity of the main chain conformation of the resulting polypeptide chain within the immunoglobulin loop. Preferably, the structurally similar sequence is 0.2 angstroms from the AP33 backbone conformation, conveniently 0.1 from the AP33 backbone conformation.
Has a backbone conformation that is within angstroms.

Preferably, the present invention is useful for the prevention of vertebrate cell infection by HCV.
Since the immunoglobulins of the present invention can neutralize each instance of HCV genotypes 1-6, the present invention is widely applicable to all HCV infections. Advantageously, since immunoglobulins are effective against all HCV genotypes, the present invention provides for HCV to be removed prior to ligand administration.
Allows testing for genotype.

In a further aspect, for the prevention or treatment of infection by two or more of HCV genotypes 1-6, comprising administering an effective amount of a ligand that binds to an epitope of HCV E2 polypeptide defined by monoclonal antibody AP33. A method is provided.

In a still further aspect, there is provided a method for the prevention or treatment of infection by two or more of HCV genotypes 1-6, comprising administering an effective amount of an immunoglobulin comprising one or more CDRs derived from monoclonal antibody AP33. Provided.

  The method of the present invention may include features as described above with respect to the use of the present invention.

The present invention further provides an immunoglobulin molecule that neutralizes HCV isolates belonging to two or more of HCV genotypes 1-6, said immunoglobulin molecule comprising one or more CDRs derived from monoclonal antibody AP33. Immunoglobulins other than monoclonal antibody AP33.

Conveniently, the one or more CDRs are
(A) RASESVDGYGNSFLH, LASNNLNS, QQNNVDPWT, GD
An array consisting of SITSGYWN, YISSYSGSTY or ITTTTYAMDY,
(B) a sequence having 1, 2 or 3 amino acid additions, substitutions or deletions from the sequence shown in (a), and (c) the sequence shown in (a) when the CDR is present in an immunoglobulin; Selected from the group consisting of structurally similar sequences.

In a preferred embodiment, the immunoglobulin has the sequence X ₁ LX ₂ NX ₃ X ₄ GX ₅ WX ₆ X ₇ (X _1
1-7 can bind to a polypeptide epitope with any amino acid at a), wherein immunoglobulin is other than monoclonal antibody AP33.

Preferably, the immunoglobulin comprises one or more human framework regions. Conveniently
An immunoglobulin includes one or more human CDRs. Methods for antibody humanization and deimmunization are known in the art, and maintain the specificity of the murine antibody while reducing or eliminating the immunogenicity of the antibody in humans so that the framework and / or CDR sequences are Substituting with a human sequence.

Unless otherwise defined, all technical and scientific terms used herein are generally defined by those of ordinary skill in the art (eg, those skilled in cell culture, molecular genetics, nucleic acid chemistry, immunology, antibody engineering and biochemistry). Has the same meaning as understood. The present invention uses conventional techniques that are within the abilities of those skilled in the art unless otherwise indicated. Such techniques are explained in the literature. For example, J. et al. Sambrook, E .; F. Fritsch, and T.R. Maniat
is, 1989, Molecular Cloning: A Laboratory M
annual, Second Edition, Books 1-3, Cold Spri
ng Harbor Laboratory Press; Ausubel, F .; M.M. e
t al. (1995 and periodic supplements; Curr
ent Protocols in Molecular Biology, ch. 9,
13, and 16, John Wiley & Sons, New York, N .; Y
. ); Harlow and Lane, Antibodies: a Laborato
See ry Manual, (1988) Cold Spring Harbor. Each of these general texts is incorporated herein by reference.

(A. Ligand)
A ligand according to the present invention can be any molecule capable of binding to a polypeptide epitope. For example, the ligand can be a protein or nucleic acid aptamer, or an immunoglobulin. The immunoglobulin molecule is in accordance with the invention two beta sheets and, usually,
It refers to the immunoglobulin superfamily, a family of polypeptides that contain the immunoglobulin fold characteristic of antibody molecules, including conserved disulfide bonds. The immunoglobulin superfamily has a broad role in the immune system (eg, antibodies, T cell receptor molecules, etc.), involvement in cell adhesion (eg, ICAM molecules) and intracellular signaling (eg, receptor molecules such as PDGF receptors). Involves many aspects of cellular and non-cellular interactions in vivo, including The invention is applicable to any immunoglobulin superfamily molecule that can bind to a target molecule. Preferably, the present invention relates to antibodies. Preferably,
The ligands according to the present invention neutralize HCV samples representing each of HCV genotypes 1-6 with an IC ₅₀ of 35 μg / ml or less, as determined by the HCV _pp neutralization assay described herein.

Conventional antibodies such as AP33 are large multi-subunit protein molecules that contain at least four polypeptide chains. For example, human IgG has two “heavy” chains and two “light” chains that are disulfide bonded to form a functional antibody. Each heavy and light chain itself comprises a “constant” (C) and “variable” (V) region. The V region determines the antigen binding specificity of the antibody, while the C region provides a function in the non-antigen specific interaction of structural support and immune effectors.

The antigen-binding specificity of an antibody or antigen-binding fragment of an antibody represents the ability of the antibody or fragment thereof to bind to a specific antigen. The antigen binding specificity of an antibody is determined by the structural characteristics of the V region. Each V region typically includes three complementarity determining regions (“CDR”, each of which includes a “hypervariable loop”) and four framework regions. Thus, the antibody binding site, which is the minimal structural unit required to bind with specific affinity to a particular desired antigen, typically retains and displays the three CDRs and the CDRs in the proper conformation. To include at least 3, preferably 4 framework regions incorporated between them.

As used herein, antibodies are Fv, ScFv, Fab ′ and F (ab ′) ₂ , dAb.
Antibody fragments capable of binding to complete antibodies or selected targets, including modified antibodies, including chimeric, CDR-grafted and humanized antibodies, and artificially selected antibodies generated using phage display or selective techniques Point to. Small molecule fragments such as dAb, Fv and ScFv are due to their small size and resulting excellent tissue distribution.
Has advantageous properties for diagnostic and therapeutic applications. Preferably, the antibody is a single chain antibody or sc
Fv.

Generally, an antibody has at least 3 recognizable CDRs or hypervariable loops and at least 3
, Preferably including 4 recognizable framework regions, in any case HCV E2
Must retain the ability to bind to proteins. Typically, but not necessarily, a polypeptide also includes a light chain constant region and / or a heavy chain constant region, preferably both. Preferred features of the polypeptide are typically as described above for the polypeptide encoded by the polynucleotide molecule of the first aspect of the invention.

In one particular embodiment, the polypeptide may comprise one or more hypervariable loops or CDRs having amino acid residue sequences substantially or completely identical to those shown in FIG. It may include one or more framework regions that have been correspondingly changed. The amino acid sequence of the polypeptide is “human framework region” and “mouse” or “foreign” CD.
Where different from the theoretical ideal of R, such deviations preferably include conservative substitutions. A conservative substitution is the replacement of another residue by one amino acid residue, both residues being in the same functional group (Figs. 2.8-2.15 of “Biochemistry” b
yL. Stryer, 2 ^nd edition W. H. With side chains within (as defined in Freeman & Co).

Polypeptides, including non-immunoglobulin polypeptides with binding activity, can be developed, for example, from a recombinant library of random polypeptide structures. Polypeptides that have binding affinity for the desired target by techniques such as phage display, SELEX, mRNA display or surface plasmon resonance, followed by improved binding specificity and affinity by repeated mutation and selection as necessary. Peptide selection is a technique known to those skilled in the art.

For example, selection of binding polypeptides by mRNA selection is described by Wilson et al, P
roc Natl Acad Sci USA 2001 Mar 27; 98 (7):
3750-3755. Srebalus and Cremme
r, Proc Natl Acad Sci USA 2001 Mar 27; 98 (
7): 3750-3755 describes the use of MALDI-TOF MS to characterize binding of a library of polypeptides to a target molecule. The use of phage display is described in Nilsson et al. , Adv Drug Deliv Rev 2000
Sep 30; 43 (2-3): 165-96 and McGregor, Mol Bio
technol 1996 Oct; 6 (2): 155-62.
The use of nucleic acid aptamers is described in Hermann and Patel, Science 20
00 Feb 4; 287 (5454): 820-5. SELE
X is a method for generating in vitro nucleic acid molecules with highly specific binding to a target molecule. It is described, for example, in US Pat. Nos. 5,654,151, 5,503,978, 5,567,588 and 5,270,163, and International Publication No. WO 96/38579.

Iterative selection procedures such as phage display and SELEX are based on the principle that there is a wide range of binding affinities for a given target in a library containing a large number of possible sequences and structures. For example, a library containing 20 subunit randomized polypeptides or nucleic acid polymers may have 4 ²⁰ structural possibilities. Those with higher affinity constants for the target are considered the most likely for binding. The partitioning, separation and amplification steps create a second nucleic acid library enriched with higher binding affinity candidates. The further number of selections progressively supports the best ligand until the resulting library is composed primarily of only one or a few sequences. These can then be cloned, sequenced and individually tested for binding affinity as a pure ligand.

The selection and mutation / amplification cycle is repeated until the desired goal is achieved. In the most general case, selection / amplification continues until no significant improvement in binding strength is achieved after repeated cycles. Selection / amplification iterations are performed in libraries containing at least 10 ¹⁴ sequences.
Sufficiently sensitive to allow isolation of individual sequence variants. The method can in principle be used to sample as many as about 10 ¹⁸ different nucleic acid species. The library preferably includes a randomized sequence portion as well as conserved sequences necessary for efficient amplification. Sequence variants can be produced in a number of ways, including synthesis of randomized nucleic acid sequences and size selection from randomly cleaved cellular nucleic acids. The variable sequence portion may comprise a fully or partially random sequence. It can also include a small portion of conserved sequences incorporated with randomized sequences. Sequence variations in the test nucleic acid may be introduced or increased by mutagenesis before or during selection / amplification iterations and by specific modifications.

The polypeptides of the present invention can be made from transformed cells or from transgenic organisms using techniques known to those skilled in the art. A typical protocol is set forth below for illustration.

((A) Transient expression of antibody in COS-7 cells)
DNA can be introduced into COS-7 cells by a number of means such as electroporation, DEAE dextran and calcium phosphate precipitation.

Regarding electroporation, Kettleborough et al (1991 Pro
tein Eng. 4,773-783) can be used. For cotransfection of heavy and light chain expression vectors, 10 μg of each vector is used. 13 μg is used for one vector expressing both antibody chains. DNA is 1 × 10 ^{7 in} PBS
Add to a 0.7 ml aliquot of cells / ml and add Bio-Rad Gene Pulser
Pulse with 1900 V, 25 μF capacitance using a registered device. As a control, 13 μg of a vector expressing a non-specific antibody is also transfected into COS-7. COS-7 cells electroporated in the absence of DNA are included as a negative control. After 10 minutes recovery at room temperature, the electroporated cells are added to 8 ml of DMEM containing 5% fetal calf serum (FCS) and incubated at 37 ° C. in 5% CO ₂ for 72 hours. After 72 hours of incubation, the medium is collected, centrifuged to remove cell debris, and stored for analysis.

Alternatively, the DEAE-dextran transfection method can be used. This method
Kriegler, M .; , Gene Transfer and Expression
: A Laboratory Manual, W.M. H Freeman and Com
pany (1990). COS-7 cells are 1 × 10 ⁶ cells / 100 m
m dish in DMEM (BIOWHITKER), 10% fetal bovine serum (FBS)
Inoculate. On day 2, the plasmid DNA is ethanol precipitated and resuspended in sterile TE (10 mM Tris, pH 8.0, 1 mM EDTA) at a concentration of 20 μg / ml. DNA
150 μl of sterile TBS (Tris buffered saline, 140 mM NaCl, 5 mM KC
l, 1.4 mM Na ₂ HPO ₄ , 25 mM Tris base, pH 7.5, 1 mM CaCl ₂
And 0.5 mM MgCl ₂ ) 300 μl and sterile DEAE dextran (SIGMA,
1 mg / ml in TBS) and mix with 300 μl. The growth medium is aspirated and the cell monolayer is washed once with PBS and once with TBS. 750 μl of DNA / DEAE dextran / TBS mixture is added to the monolayer. The dish is incubated for 1 hour at ambient temperature in a laminar flow hood with rocking every 5 minutes. After 1 hour incubation, the DNA solution is aspirated,
Cells are washed once with TBS and then once with PBS. Cells were treated with 100 μM chloroquine (S
Incubate in complete medium supplemented with IGMA) at 37 ° C., 5% CO ₂ . After 4 hours, the medium is replaced with complete medium and the cells are incubated at 37 ° C., 5% CO ₂ . Forty-eight hours after transfection, the cells are fed with DMEM growth medium without serum. 2
After 4 hours, the medium is collected and centrifuged for 5 minutes at 1500 rpm in a tabletop clinical centrifuge to remove cell debris.

((B) Stable expression of the antibody of the present invention in CHO cells)
A typical protocol for this procedure is as follows.
CHO cells (CHO DUXB-11, Urlaub & Chasin, 1980
Proc. Natl. Acad. Sci. USA 77,4216-4220) is trypsinized and washed once in phosphate buffered saline (PBS). DNA (plasmid containing genes for 13 μg heavy and light immunoglobulin chains) and 1 × 10 ⁷ cells / ml in PBS
0.8 ml aliquots of sterile Gene Pulser® cuvettes (0.4
cm gap). The pulse is delivered at 1900 volts, 25 μF capacitance. After a 10 minute recovery period at room temperature, the electroporated cells are added to 20 ml α-MEM (plus ribonucleoside and deoxyribonucleoside) / 10% FBS. After 24-48 hours incubation, cells are trypsinized and plated in 100 mm dishes in α-MEM (minus ribonucleosides and deoxyribonucleosides) / 10% dialyzed FBS (to select for expression of dhfr-containing plasmids). The medium is changed every 3-4 days until colonies appear. Single clones are isolated by cloning cylinders, propagated and analyzed for IgG production by ELISA. Next, gradually increasing Ig
In order to select clones expressing G, a single clone is subjected to successively increasing concentrations of methotrexate (MTX) (starting with 10 ⁹ M ⁻¹ MTX). The medium is changed every 3-4 days until colonies appear. Single clones are isolated by cloning cylinders, propagated and analyzed for IgG production by ELISA.

((C) Enzymatic production of antibody fragments)
Antigen-binding antibody fragments can be produced by enzymatic or chemical separation of intact immunoglobulins. Fragments can also be obtained by recombinant DNA techniques (eg King et
al, 1992 Biochem. J. et al. 281, 317-323; Carter et
al, 1992 Biotechnology 10,163-167). A segment of nucleic acid encoding the selected fragment is produced by digestion of the full length coding sequence with appropriate restriction enzymes or by de novo synthesis.

For example, the F (ab ′) ₂ fragment has been described by Harlow & Lane (1988 “An
tibodies, A Laboratory Manual ", Cold Spring
g Harbor Laboratory, NY) and can be obtained from IgG molecules by proteolytic digestion with pepsin at pH 3.0-3.5 using standard methods.

Fab fragments can be obtained from F (ab ′) ₂ fragments by limited reduction or from intact antibodies by digestion with papain in the presence of a reducing agent.

The polypeptides of the present invention may be characterized in a number of ways that will be apparent to those skilled in the art. These are E
Includes physical measurement of concentration by techniques such as LISA and physical measurement of antibody purity by SDS-PAGE. In addition, the effectiveness of the polypeptide can be determined in HCV E in solution or in a solid phase system such as an ELISA, surface plasmon resonance (eg BIA core) or immunofluorescence assay.
It can be measured by detecting the binding of the molecule to the two glycoproteins. More particularly, HCs representing six known genotypes in an HCV _pp neutralization assay as described herein.
Polypeptides can be tested for neutralizing ability against V samples.

The polypeptides of the present invention may contain non-amino acid moieties. For example, the polypeptide can be glycosylated. Such glycosylation can occur naturally during expression of the polypeptide in the host cell or host organism, or can be an intentional modification resulting from human intervention. Additionally or alternatively, the polypeptides of the invention may be subjected to other chemical modifications. One such desirable modification is the addition of one or more polyethylene glycol (PEG) moieties. PEGylation has been shown to significantly increase the half-life of various antibody fragments in vivo (
Chapman 2002 Adv. Drug Delivery Rev. 54, 53
1-545). However, random pegylation of antibody fragments can have a very detrimental effect on the binding affinity of the fragment for the antigen. To avoid this, pegylation should be limited to specific target residues of the antibody or antibody fragment (
Knight et al., 2004 Platelets 15, 409-418 and Chapman, cited above).

(B. Antibody production)
Antibodies according to the present invention are antibodies that are conveniently made, for example, so that they have a primary sequence that is different from the temporary sequence of a naturally occurring antibody. In particular, the AP33 antibody is preferably modified.

An antibody according to the present invention that does not have a native AP33 sequence may be a modified AP33 that includes a fragment of AP33, one or more additions, substitutions or deletions in the amino acid sequence, the addition of a label or an effector group, and the like. Conveniently, the antibody has been humanized or deimmunized to make it less immunogenic in a human subject.

Antibodies useful in the present invention can be generated de novo or can be produced by manipulating AP33.

(B (i) New antibody production)
Antibodies can be generated by animal or human immunization using the peptide immunogens described herein. Antibodies can be obtained from the sera of immunized animals or can be produced in cell culture. Recombinant DNA technology can be used to produce antibodies according to established procedures in bacterial or preferably mammalian cell culture. The selected cell culture system preferably secretes the antibody product.

General methods for producing monoclonal antibodies by hybridomas are well known. The production of non-human monoclonal antibodies, such as mouse, rabbit and horse monoclonal antibodies, is well known and can be performed, for example, by immunizing an animal with a formulation containing HCV E2 glycoprotein or a fragment thereof. Antibody-producing cells obtained from the immunized animal are immortalized and screened, or initially screened for production of antibodies that bind to E2, and then immortalized. (See Harlow & Lane cited above).

Immortal antibody-producing cell lines can be established by cell fusion and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA or transfection with Epstein-Barr virus. A panel of monoclonal antibodies produced against the HCV E2 epitope can be screened for various properties, such as isotype and epitope affinity.

HCV E2-containing polypeptides can also be used to select human monoclonal antibodies. For example, some human antibodies that have the same epitope specificity as a particular mouse antibody, such as AP33, can be selected by competitive binding experiments. Such antibodies are particularly likely to share the useful HCV neutralizing properties revealed for AP33. Human antibodies against HCV E2 can be generated by screening DNA libraries from human B cells (Huse et al, 1989 Science 246, 1275-1).
281). An antibody that binds to HCV E2 or a fragment thereof is selected. The sequence encoding such an antibody (or binding fragment) can then be cloned and amplified. This protocol can be improved by combination with phage display technology (eg, WO 91/17271 and WO 92/0104).
7 brochure).

Growth of hybridoma cells or mammalian host cells in vitro can be accomplished using any suitable standard medium, such as mammalian serum, such as fetal bovine serum, or trace elements and growth maintenance supplements, such as normal mouse peritoneum. Dulbecco's modified eagle medium (DMEM) supplemented with support cells such as exudate cells, spleen cells, bone marrow macrophages, 2-aminoethanol, insulin, transferrin, low density lipoprotein, oleic acid, etc.
Alternatively, it is performed in RPMI 1640 medium. Growth of host cells, which are bacterial cells or yeast cells, can also be achieved by any suitable medium known in the art, such as LB, NZ for bacteria.
CYM, NZYM, NZM, terrific broth, SOB, SOC, 2 × YT or M9 minimal medium, and for yeast, medium YPD, YEPD, minimal medium or complete minimal dropout medium.

In vitro production provides a relatively pure antibody formulation and allows scale-up to give a given large amount of the desired antibody. Techniques for bacterial cell, yeast or mammalian cell culture are known in the art, such as homogeneous suspension culture in airlift reactors or continuous stirred reactors, or in hollow fibers, microcapsules, agarose microbeads or ceramics. Includes immobilization on cartridge or entrap cell culture.

Large quantities of the desired antibody can also be obtained by growing mammalian cells in vivo. For this, hybridoma cells producing the desired antibody are injected into histocompatible mammals that cause the growth of antibody-producing tumors. Optionally, animals are primed with hydrocarbons, especially mineral oils such as pristane (tetramethyl-pentadecane) prior to injection. After 1-3 weeks, antibodies are isolated from the body fluids of those animals. For example, hybridoma cells obtained by fusion of antibody-producing spleen cells from Balb / c mice with appropriate myeloma cells, or transfected cells derived from hybridoma cell line Sp2 / 0 that produces the desired antibody, optionally with pristane. Treated Balb / c mice are injected intraperitoneally and ascitic fluid is collected from the animals after 1-2 weeks.

These and other techniques are described in, for example, Kohler and, which are incorporated herein by reference.
Milstein, (1975) Nature 256: 495-497; U.S. Pat. No. 4,376,110; Harlow and Lane, Antibodies.
: A Laboratory Manual, (1988) Cold Spring H
Discussed in arbor. Techniques for the preparation of recombinant antibody molecules are described in the above references and also, for example, European Patent No. 0623679; European Patent No. 0368684 and European Patent No. 0436597, which are incorporated herein by reference. Is described in the book.

Cell culture supernatants are screened for the desired antibody by immunofluorescence staining of cells that preferentially express the desired target, by immunoblotting, by enzyme immunoassays, such as sandwich assays or dot assays, or by radioimmunoassays. The

For antibody isolation, immunoglobulins in the culture supernatant or ascites can be concentrated, for example, by precipitation with ammonium sulfate, dialysis against hygroscopic materials such as polyethylene glycol, filtration through selective membranes, and the like. Where necessary and / or desired, conventional chromatographic methods such as gel filtration, ion exchange chromatography, chromatography on DEAE-cellulose and / or (immuno) affinity chromatography,
The antibody is purified, for example, by affinity chromatography with the target molecule or protein A.

Antibodies produced according to the above procedure can be cloned by isolation of nucleic acids from cells according to standard procedures. Usefully, the nucleic acid variable domains of antibodies can be isolated and used to construct antibody fragments such as scFv.

Fully human antibodies specific for any desired polypeptide can also be generated by selection from a library or in transgenic mice carrying a human antibody gene repertoire.

Various techniques for the selection of antibodies from libraries have been described and Hoogenb
oom (2005) Nature Biotechnology 23, 1105-11
16 is reviewed. Briefly, methods that can be used for antibody library selection include phage display, ribosome display and microbial cell display.

Any library selection system can be used with the present invention. Selection protocols for isolating the desired number of large libraries are known in the art, as represented by phage display techniques. Such a system in which various peptide sequences are presented on the surface of filamentous bacteriophages (Scott and Smith (1990, supra) is an antibody fragment for in vitro selection and amplification of specific antibody fragments that bind to a target antigen (and The nucleotide sequences encoding them) have been found to be useful for constructing a library of nucleotide sequences encoding the V _H and V _L regions.
Ligating them to a gene fragment encoding a leader signal that directs them to the periplasmic space of E. coli, and the resulting antibody fragment is typically as a fusion to a bacteriophage coat protein (eg, pIII or pVIII) Presented on the surface of bacteriophage. Alternatively, the antibody fragment may be a λ phage capsid (
It is displayed outside the phage body). An advantage of phage-based display systems is that, since they are biological systems, the selected library construct can be amplified simply by growing the phage containing the selected library construct in bacterial cells. Furthermore, since the nucleotide sequence encoding the polypeptide library construct is contained in a phage or phagemid vector, sequencing, expression and subsequent genetic manipulation is relatively easy.

Methods for the construction of bacteriophage antibody display libraries and lambda phage expression libraries are well known in the art (incorporated herein by reference, M
cCafferty et al (1990) supra; Kang et al. (199
1) Proc. Natl. Acad. Sci. U. S. A. 88: 4363; Cla.
ckson et al. (1991) Nature, 352: 624; Lowman.
et al. (1991) Biochemistry, 30: 10832; Burton
et al (1991) Proc. Natl. Acad. Sci U. S. A. , 88
: 10134; Hoogenboom et al. (1991) Nucleic Ac
ids Res. 19: 4133; Chang et al. (1991) J Imm
unol, 147: 3610; Breitling et al (1991) Gene,
104: 147; Marks et al. (1991) Above; Barbas et a
l. (1992) supra; Hawkins and Winter (1992) J. MoI. Imm
unol, 22: 867; Marks et al, 1992, J Biol. Chem
. , 267: 16007; Lemer et al (1992) Science, 258
: 1313).

One particularly advantageous approach was the use of an scFv phage library (Hu
ston et al, 1988, Proc. Natl. Acad. Sci U. S. A
. 85: 5879-5883; Chaudhary et al (1990) Proc.
. Natl. Acad. Sci U. S. A. , 87: 1066-1070; McCa
ferty et al. (1990) supra; Clackson et al. (19
91) Above; Marks et al (1991) Above; Chiswell et al.
(1992) Trends Biotech. , 10:80; Marks et al.
(1992) above). Various embodiments of scFv libraries displayed on bacteriophage coat proteins have been described. Refinements of the phage display approach are also known, eg, WO 96/06213 and WO 92/01047 (Medical Res), which are incorporated herein by reference.
search Council et al. ) And WO 97/08320 (Morphosys, supra).

In the phage display method, a library of phage displaying various antibodies or fragments on their outer surface is created. Antibodies are usually presented as scFv or Fab fragments. Phages displaying antibodies with the desired specificity are selected by enhanced affinity for the HCV E2 polypeptide or fragment thereof.

In a modified phage display method, human antibodies having the binding specificity of selected mouse MAbs such as AP33 can be prepared (see WO 92/20791 pamphlet). In this approach, the heavy or light chain variable region of a selected mouse antibody (eg, AP33) is used as a starting material. For example, if a light chain variable region is selected as the starting material, a phage library is constructed that displays the same light chain variable region (ie, mouse starting material) and a different heavy chain variable region. The heavy chain variable region is obtained from a library of rearranged human heavy chain variable regions. A phage is selected that exhibits strong specific binding to HCV E2 glycoprotein (eg, at least 10 ⁸ , preferably at least 10 ⁹ M ⁻¹ ). The human heavy chain variable region from this phage then serves as starting material for the construction of additional phage libraries. In this library, each phage displays the same heavy chain variable region (ie, a region identified from the original display library) and a different light chain variable region. The light chain variable region is obtained from a library of rearranged human light chain variable regions. Again, HCV
Select phages that show strong specific binding to E2. These phage display the variable region of a fully human HCV E2 antibody. These antibodies usually have the same or similar epitope specificity as the mouse starting material. As this variant, selection may additionally or alternatively be based on the ability to neutralize all six genotypes of HCV.

The HCV E2-binding polypeptides of the present invention can also be expressed and purified from transgenic organisms such as transgenic goats, mice or plant systems. Production of recombinant antibodies in plants is described by Schillberg et al, (2005 Vac
cine 23, 1764-1769 and 2003 Cell Mol. Life
Sci. 60, 433-445). Plants that have been successfully used for expression of antibodies or antibody fragments are Arabidopsis De Wilde et al, 1998 Plant Cell Phy.
siol. 39, 639-646) and tobacco (Valdes et al, 2003).
Biochem. Biophys. Res. Comm. 308, 94-100).

Once expressed, a complete antibody or antibody fragment of the invention can be purified according to standard techniques in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis, etc. (generally Scopes & Stutter, 198
2 Methods Enzymol. 90 Part E, 479-490). For pharmaceutical use, substantially pure immunoglobulins of at least about 90-95% homogeneity are preferred, and 98-99% or more homogeneous immunoglobulins are most preferred.

Selective library selection technologies, both as described earlier (Hu
se et al. (1989) Science, 246: 1275; Caton an
d Koproski (1990) Proc. Natl. Acad. Sci. U. S.
A. 87; Mullinax et al. (1990) Proc. Natl. Aca
d. Sci. U. S. A. 87: 8095; Persson et al. (1991
) Proc. Natl. Acad. Sci. U. S. A. 88: 2432), including bacteriophage lambda expression systems that can be directly screened as bacteriophage plaques or as lysogen colonies and are useful in the present invention. Such expression systems can be used to screen up to 10 ⁶ different components of the library, but they are not practically suitable for larger numbers (10 ⁶ or more). Other screening systems are based on, for example, direct chemical synthesis of library components. One early method is
It involves the synthesis of peptides on a set of pins or rods as described in WO 84/03564. A similar method involving peptide synthesis on beads forming a peptide library where each bead is an individual library component is described in US Pat. No. 4,631,211 and related methods. International Publication No. 92/00091
It is stated in the issue pamphlet. A significant improvement of the bead-based method involves labeling each bead with a unique identification tag, such as an oligonucleotide, to facilitate identification of the amino acid sequence of each library component. These improved bead-based methods are described in WO 93/06121.

Another method of chemical synthesis is to synthesize an array of peptides (or peptidomimetics) on the surface by placing each different library component (eg, unique peptide sequence) at a predetermined, spaced position within the array. including. The identity of each library component is determined by its spatial location in the array. The location in the array where binding interactions occur between a given molecule (eg, a receptor) and the reactive library construct is determined, thereby identifying the sequence of the reactive library construct based on the spatial location. These methods are described in US Pat. No. 5,143.
No. 854; WO 90/15070 and WO 92/1009.
No. 2; Fodor et al. (1991) Science, 251: 767;
Dower and Fodor (1991) Ann. Rep. Med. Chem. , 2
6: 271.

Other systems for generating polypeptides or nucleotide libraries include the use of cell-free enzyme mechanisms for in vitro synthesis of library constructs. In one method, RNA molecules are selected by alternating selection for a target ligand and PCR amplification (Tuerk and Gold (1990) Science, 249: 505).
Ellington and Szostak (1990) Nature, 346: 8;
18). A similar approach can be used to identify DNA sequences that bind to a given human transcription factor (Thiesen and Bach (1990) Nucleic Acids).
Res. , 18: 3203; Beaudry and Joyce (1992) Scie.
nce, 257: 635; WO 92/05258 and WO 9
2/14843 pamphlet). Similarly, in vitro translation can be used to synthesize polypeptides as a method for creating large libraries. These methods generally involving stabilized polysome complexes are further described in WO 88/08453, WO 90/05785, WO 90/07003, WO 91/02076. , WO 91/05058 pamphlet and WO 92/02536 pamphlet. WO95 / 22625 pamphlet and WO95 / 11922 pamphlet (Af
Selective display systems that are not based on phage, as described in fymax) use polysomes to display polypeptides for selection. These and all the aforementioned materials are also incorporated herein by reference.

An alternative to the use of phage or other cloned libraries is to use nucleic acids, preferably RNA, derived from the spleen of animals immunized with the selected target. The RNA thus obtained represents a natural library of immunoglobulins. MRN of V region and C region
Isolation of A allows antibody fragments such as Fab or Fv to be expressed intracellularly according to the present invention.

Briefly, RNA is isolated from the spleen of an immunized animal and R primers are used using PCR primers.
Selectively amplify V _H and V _L cDNA from the NA pool. The V _H obtained in this way
And _VL sequences are ligated to generate scFv antibodies. PCR primer sequences are based on published V _H and V _L sequences and are commercially available in kit form.

In combination with all selection and display systems, the present invention provides peptides that have been identified to form an epitope that is bound by AP33 for isolation of the desired binding activity. Such peptides are described in more detail herein.

(Production of B (ii) AP33)
AP33 or other antibodies that share the epitope specificity of AP33 may be engineered to reduce immunogenicity and / or improve binding properties.

Several techniques for manipulating antibodies are known in the art. In general, transfer of CDRs from a donor (non-human) antibody to a recipient (human) antibody framework reduces the immunogenicity of the antibody. This procedure is known as CDR grafting or humanization. The difficulty with this procedure is that binding activity can be lost as a result of differences between the donor and acceptor frameworks. Furthermore, a certain amount of immunogenicity can be retained by the CDR itself. Thinning,
Various supplemental and selective approaches have been proposed to address these issues, including resurfacing, SDR transfer and deimmunization.

Preferably, the polynucleotide of the present invention encodes a CDR grafted molecule. The CDR grafting molecule includes a light and / or heavy chain CDR having an amino acid sequence substantially or completely identical to the light or heavy chain CDR sequence of AP33 shown in FIG. 8, and the framework region sequence of AP33 shown in FIG. And a framework region that is not substantially the same. For the present invention, a CD
R is different from the corresponding CDR sequence shown in FIG. 8 by 1 or 2 amino acid residues, preferably by 1 amino acid residue (ie, preferably each compared to the CDR sequence of AP33 shown in FIG. 8). Substitution of only one amino acid residue within the CDR of the Preferably, the CDR sequence of the CDR grafting molecule is the A shown in FIG.
It is completely identical to the CDR sequence of P33.

A particularly preferred type of CDR-grafted molecule is an antibody or antigen-binding fragment comprising a CDR having an amino acid sequence substantially or completely identical to that of AP33 shown in FIG. 8, but comprising a human framework region sequence. Such molecules can be referred to as “humanized”. The use of altered framework regions compared to that of AP33 because it more closely resembles (or even is identical to) that of a human antibody greatly reduces the immunogenicity of the resulting polypeptide in human subjects. Should be (compared to AP33). A “human framework region sequence” is an amount that is identical or insignificant to that of a human antibody (eg, 7 amino acid residues or less per framework region, preferably 4 residues or less per framework region,
More preferably, it is 3 residues or less per framework region, most preferably 2 residues or less per framework region). Conveniently, the encoded polypeptide comprises the same framework region as that encoded by the human germline antibody gene segment.

In general terms, “CDR grafting” involves the formation of a polynucleotide encoding a CDR from a non-human source (such as a mouse or other non-human mammal) in combination with a human framework region. The constant region, if present, is preferably of human origin.

Conventionally, the terms “donor antibody” and “acceptor antibody” are used. CDRs from non-human donor antibodies are grafted into the framework of human acceptor antibodies. CDR grafting techniques are well known to those skilled in the art. The procedure was first described in Jones et al, (1986 Nature 3
21, 522-525) and Riechmann et al, (1988 Nature).
e 332, 323-327) and included only the transplantation of CDRs of non-human origin into the human framework.

This approach may require additional transfer of certain framework residues outside the CDRs into the grafted antibody (Riechmann et al, (1988) Nat.
ure 332, 323-327). Thus, as used herein, the term “CDR grafting” should not be construed to simply mean the transfer of CDR residues to a different framework, but confers the antigen-binding properties of the antibody from which the CDR is derived to the resulting molecule. Additional imports of such framework residues are also included as the substantial need arises. "CDR grafting molecule"
The term should be construed accordingly to encompass polypeptides that are simultaneously “grafted” with certain framework residues in addition to the CDRs.

For example, humanization of an antibody is described in European Patent No. 460167, European Patent No. 682040, US Pat. No. 5,530,101, No. 5585089, No. 569.
No. 3761, No. 5673762, No. 5766886, No. 5
No. 821337, No. 5859205, No. 5886152, No. 5887293, No. 5955358, No. 6054297 and No. 6180370. Yes. All of these methods involve redesigning the antibody variable region such that the amino acid residues responsible for conferring antigen binding specificity are incorporated within the framework regions of the human antibody variable region.

In some cases, the immunogenic portion of the non-human antibody is replaced with a residue from a human antibody (
For example, US Pat. No. 5,712,120). Alternatively, residues on the surface of an antibody variable domain can be replaced with residues from a human antibody to “resurface” the non-human variable domain (eg, US Pat. No. 5,636,641). Resurface creation is Padl
an (1991, European Patent No. 0519596), which is also referred to as “veneering”. In this approach, the first (donor equivalent-C
The solvent contact residue of the DR source) antibody is replaced by the residue from the second (“acceptor”) antibody. Typically, the second antibody is a human antibody. Solvent non-contact residues, CDRs, interdomain contact residues, and residues immediately adjacent to the CDRs all remain the same as in the first antibody. This strategy is intended to mimic the surface of the second antibody while preserving all of the packing and interface interactions from the first antibody that would help maintain full antigen binding activity. This should reduce the number of B cell epitopes (and also reduce some T epitopes), leading to lower immunogenicity.

Solvent contact residues are identified by examination of the high resolution structure of the antibody. Other regions of the antibody thought to be related to humanization, ie buried residues that contact the CDRs and differ between mouse and human antibodies (in which case rodent residues are used), or both An N-terminal region that is located near the CDRs with respect to the domain, and is thought to play a role in antigen binding, and an electrostatic interaction that may play a role even at a distance. The selection of surface residues to replace is determined by homology matching between the first antibody variable domain and the domain of the available sequence (individual or consensus sequence) from the second antibody species.

U.S. Pat. No. 5,636,641 and European Patent Application Publication No. 0592106 describe alternative methods for resurface preparation. Here, the solvent accessible residue to be changed to the residue of the second antibody species is identified using a procedure similar to Padlan, but a larger number of structures are used to obtain the average accessibility for each position. analyse. Residues with a certain level of accessibility are considered and changed to residues from the antibody from the species for which the antibody is to be used. The selection of residues to replace can be from antibodies with overall homology or from antibodies with the highest homology when considering only solvent accessible residues.

The humanization methods described in WO 93/17105 and US Pat. No. 5,766,686 identify low risk residues that can normally be safely changed to human equivalents. These residues tend to be solvent accessible. Thus, if only the solvent accessible residue is changed, this step is similar to the resurfacing method.

EP-A-0438310 and EP-A-0519959 which describe two additional approaches that have the net effect of providing resurfaced or thinned antibodies.
See No. 6 specification.

Further approaches identify and eliminate T cell epitopes in order to disable or reduce T cell helper functions for the immune response, leading to a minimal immune response to the introduced antibody ( (Referred to as “detope”) (US Pat. No. 5,712,120; European Patent Application No. 069755). It is also possible to remove B cell epitopes in this step.

“Deimmunization” technology is based on B and T within antibody sequences.
It seeks to reduce both cellular epitopes and relies on prediction algorithms and also structural information to model MHC peptide binding sites to identify these motifs. See European Patent No. 98/52976, European Patent No. 0983033, International Patent Publication No. 00/34317, European Patent No. 1051432.

Antibody humanization techniques are also described in “Antibody Engineering” (Eds.
intermann and Dhubel), Chapter 40 p567-59.
2 (O'Brien and Jones).

Some studies have found that not all CDRs come into contact with antigens,
For example, MacCallum et al, (1996 J. Mol. Biol. 262
732-745). Thus, in some cases, humanization can be achieved by transfer of a subset of CDR residues, eg, Santos & Padlan (1988, Prog
. Nucl. Acid Res. Mol. Biol. 60, 169-194) and Tam
ura et al, (2000, J. Immunol. 164, 1434-1441).
Shown in This is referred to as SDR import.

(B (iii). Binding humanization and selection)
Uncertainty in the relative importance of the framework is a factor in the success of humanization in the development of various methods, and has led in part to various selection promotion library methods.
These aim to practically identify the best binding partners from a population of selective combinations. For example, use of a library of specific antibody variable domains with variability at one or more framework positions to test humanized variants (see, eg, Baca et al. (
1997) J. MoI. Biol. Chem. 272: 10678),
Use of a library of variable region frameworks in combination with CDR3 from specific sources (eg Rader et al. (1998) PNAS 95: 8910),
Selection of human partner domains from within libraries to replace non-human antibody variable domains to form human antibodies or human antibody binding sites of specific affinity and specificity (eg, Guided selection, Jespers et al. 1994). Bi
oTechnology 12: 899; Beiboer et al. , (2000)
J. et al. Mol. Biol. 296: 833),
CDR3 to obtain specific binding (eg HuCal: Knappick et al
. (2000) J. Am. Mol. Biol. 296: 57) or use a specific framework with a library of all CDRs.

Wu et al (1999 J. Mol. Biol. 294, 151-162)
A procedure for improving the simultaneous affinity of humanized and humanized antibodies was described (US Pat. No. 595,535).
(See also specification 8). Combinatorial libraries are intensive CDRH3 and C
Eight potentially important framework locations were considered with the DRL3 library. A number of anti-CD40 Fab variants were identified that contain only one mouse framework residue and show an affinity about 500-fold higher than the original chimeric Fab.

Phage display technology provides a powerful method for selecting such immunoglobulins (WO 91/17271, WO 92/01).
No. 047 pamphlet, International Publication No. 92/06204 pamphlet). Thus, for example, humanization of antibodies involves Hoogenboom using phage display and bacterial cells.
Using the epitope “imprint” approach (eg Hoogenboom & Wint
er 1992, J. et al. Mol. Biol. 227, 381-388; H
oooenboom 2002 Methods Mol. Biol. 178, 1-37
and 2005 Nature Biotechnol. 23, 1105-1116
Reviewed by Vaccinex Inc.). (For example, US 2005 /
Can be achieved using the vaccinia virus display library and its modified version using mammalian cells, as developed by U.S. Pat. No. 2,664,425.

(C. Polynucleotide)
The present invention provides polynucleotides that encode the polypeptide ligands described herein. The polynucleotides of the invention can encode any polypeptide having the desired HCV E2 binding activity.

For example, a polynucleotide can encode an entire immunoglobulin molecule chain, such as a light or heavy chain. A complete heavy chain is not only a heavy chain variable region (V _H ), but typically a heavy chain constant region (C _H ) comprising three constant domains, namely C _H 1, C _H 2 and C _H 3, And a “hinge” region. In some situations, the presence of a constant region is desirable. For example, if the antibody desires to kill HCV-infected cells, the presence of a complete constant region is desirable to activate complement. However, in other situations, the presence of a completely stationary region may not be desirable. For example, if antibodies are required for imaging, the presence of constant regions can reduce tissue penetration due to increased molecular size.

Other polypeptides that can be encoded by the polynucleotide include single domain antibodies ("
dAb "), Fv, scFv, Fab 'and F (ab') ₂ and antigen-binding antibody fragments such as" miniantibodies ". Miniantibodies are (typically) bivalent antibody fragments in which the C _H 1 and C _K or C _L domains have been removed. Because miniantibodies are smaller than conventional antibodies,
Better tissue penetration should be achieved in clinical / diagnostic applications, but because it is bivalent, it should retain higher binding affinity than a monovalent antibody fragment such as a dAb. Thus, unless the context indicates otherwise, the term “antibody” as used herein encompasses not only complete antibody molecules, but also antigen-binding antibody fragments of the type discussed above.

In certain embodiments, the invention provides a polynucleotide sequence that encodes a polypeptide comprising at least three immunoglobulin hypervariable heavy or light chain loops, wherein the polypeptide retains antigen binding and has three complementary sequences. Representative of each of HCV genotypes 1-6 when combined with a polypeptide comprising an immunoglobulin hypervariable light or heavy chain loop with an IC ₅₀ of 35 μg / ml or less as determined by the HCV _pp neutralization assay described herein. To form antibody molecules or fragments thereof that neutralize the HCV sample.

The hypervariable loop encoded by the polynucleotide may have an amino acid sequence that is preferably identical or substantially identical to the amino acid sequence of the hypervariable loop present in AP33. The loop is described in Kabat et al, (1991, Sequences of Immun.
ological Interest, 5 ^th Edn. US Dept. Health
and Human Services, Washington D .; C. ), The amino acid residues 24 to 24 in the AP33 light chain as shown in FIG.
34, 50-56 and 87-89 and 31-35B, 50-65 and 9 in the AP33 heavy chain.
5 to 102.

The encoded polypeptide typically has the same or substantially the same CDR sequence as AP33, but the framework regions are preferably different from AP33. Accordingly, the polynucleotide of the present invention is a polynucleotide having a heavy and / or light chain variable region containing amino acid residue substitutions, particularly within the framework region, as compared to the heavy and / or light chain (as appropriate) of AP33 Encodes the peptide. If the encoded polypeptide contains a partial or complete heavy and / or light chain constant region, it may also contain substitutions compared to the constant region of AP33.

The effect of substitution is that compared to AP33, the encoded polypeptide
(I) high affinity for binding to HCV E2 protein (eg as measured by standard ELISA), and / or (ii) high specificity for binding to HCV E2 protein (ie with other proteins, particularly human proteins) Low cross-reactivity), and / or (iii) 1 of HCV as measured by the HCV _pp neutralization assay described herein.
Low IC ₅₀ for neutralization of the above genotypes, and / or (iv) low immunogenicity in human subjects (eg, after a standard dose of the encoded polypeptide is administered intravenously to a human subject followed by a standard ELISA) Determined by the measured anti-idiotype response)
Can be included.

Preferably, at least one of the encoded polypeptide framework regions, most preferably each of the framework regions, is human in order to reduce the immunogenicity (as compared to AP33) in human subjects of the resulting polypeptide. A to be more similar to that of an antibody
Contains amino acid substitutions compared to P33.

Preferably, each framework region present in the encoded polypeptide contains at least one amino acid substitution compared to the corresponding AP33 framework. Therefore, for example, the framework area is a total of 3, 4, 5, 6, 7, 8, 9, 10, 11 in comparison with the framework area existing in the AP 33. , 12 pieces, 1
It may contain 3, 14 or 15 amino acid substitutions.

It is possible that the hypervariable loop of the polypeptide encoded by the polynucleotide may also contain a total of one or more amino acid substitutions compared to the amino acid sequence of AP33 as shown in FIG. The encoded polypeptides are for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 compared to the hypervariable loop sequence of AP33, for example. Or it may contain 12 amino acid substitutions (in the heavy and / or light chain). In general, it is assumed that the encoded polypeptide has substantially the same, preferably the same CDR or hypervariable loop sequence as in AP33, although in some cases each of the hypervariable loops is an AP33 hypervariable loop sequence. As compared to at least one amino acid substitution.

Preferably, the polynucleotides and / or polypeptides of the present invention are isolated and / or purified. The term isolated is intended to indicate that the molecule has been removed or separated from its natural or natural environment, or produced in a manner that does not exist in its natural or natural environment. The term purification is intended to indicate that at least some of the contaminating molecules or substances have been removed. Preferably, the polynucleotide and / or polypeptide is substantially such that the related polynucleotide and / or polypeptide constitutes the predominant (ie most abundant) polynucleotide or polypeptide present in the composition. To be purified.

Accordingly, the present invention preferably uses a recombinant nucleic acid comprising an insert encoding an antibody heavy chain variable domain and / or light chain variable domain. By definition, such nucleic acids include single stranded encoding nucleic acids, double stranded nucleic acids composed of said encoding nucleic acids and nucleic acids complementary thereto, or their complementary (single stranded) nucleic acids themselves.

Furthermore, the nucleic acid encoding the heavy chain variable domain and / or the light chain variable domain of the antibody is an enzymatic having a genuine sequence encoding a naturally occurring heavy chain variable domain and / or light chain variable domain, or a mutant form thereof. Or it may be a chemically synthesized nucleic acid. A mutated form of the authentic sequence has one or more amino acids deleted or replaced with one or more other amino acids,
A nucleic acid encoding the heavy chain variable domain and / or the light chain variable domain of the antibody. Preferably, the modification is outside the CDRs of the antibody heavy chain variable domain and / or light chain variable domain. Such mutant nucleic acids are also intended to be silent mutants in which one or more nucleotides are replaced by other nucleotides having new codons encoding the same amino acid. Such mutant sequences are also degenerate sequences. A degenerate sequence is degenerate within the meaning of the genetic code in that an unlimited number of nucleotides are replaced by other nucleotides without causing a change in the originally encoded amino acid sequence. Such degenerate sequences are those different restriction sites and / or specific codons preferred for a particular host, particularly yeast, bacteria or mammalian cells, in order to obtain optimal expression of the heavy chain variable domain and / or light chain variable domain. Can be useful because of their frequency of use.

The invention further provides a nucleic acid construct comprising a polynucleotide according to the first aspect of the invention. Typically, the construct is an expression vector that allows expression of the polypeptide encoded by the polynucleotide in a suitable host. The construct may include, for example, one or more of the following. That is, it may contain one or more regulatory sequences such as a promoter and enhancer active in the host, an origin of replication and a marker, preferably a selectable marker. The host can be a eukaryotic or prokaryotic host, although eukaryotic (especially mammalian) hosts are considered preferred. The choice of an appropriate promoter obviously depends to some extent on the host cell used, but H
It may contain promoters from human viruses such as SV, SV40, RSV and the like. Numerous promoters are known to those skilled in the art.

The construct may comprise a polynucleotide encoding a polypeptide comprising three light chain hypervariable loops or three heavy chain hypervariable loops. Alternatively, the polynucleotide may encode a polypeptide comprising three heavy chain hypervariable loops and three light chain hypervariable loops connected by a suitably flexible linker of appropriate length. Another possibility is that a single construct may contain a polynucleotide encoding two separate polypeptides—one containing a light chain loop and one containing a heavy chain loop. Separate polypeptides can be expressed independently or can form part of one common operon.

Nucleic acid constructs encoding HCV E2 binding polypeptides of the invention can be used, for example, in oligonucleotide-induced site-directed mutagenesis (see, eg, Carter et al, 1986)
Proc. Natl. Acad. Sci. USA 83, 8127-8131) and PCR (Ho et al, Gene 1989 77, 51-59) and can be made using standard recombinant nucleic acid techniques well known to those skilled in the art.

The invention further provides an in vitro host cell comprising a polynucleotide or construct as defined above. Host cells can be bacteria, yeast or other fungal cells, insect cells, plant cells or mammalian cells. The present invention may also provide a transgenic multicellular host organism that has been genetically engineered to produce a polypeptide according to the present invention. The organism can be, for example, a transgenic mammal (eg, a transgenic goat or mouse system) or a transgenic plant system. Methods for producing polypeptides are further described below.

(D. Immunogen)
In a further aspect, the present invention provides a composition for introducing an antibody that binds to hepatitis C virus (HCV) E2 glycoprotein, said composition comprising the amino acid residue sequence XLXNXX
Comprising a peptide having GXWXX and a physiologically acceptable carrier, excipient or diluent, said peptide optionally comprising additional amino acid residues at the N and / or C terminus, although HCV
It does not include the entire E2 glycoprotein or its E2 ₆₆₀ fragment (ie, residues 384-660 of the HCV polyprotein), and one or more of the amino acid residues may be covalently modified.

Also, two or more of the X residues in the sequence may be the same, or any X residue may be different.

X can be any of the naturally occurring amino acid residues or, more preferably,
It may be a non-conventional residue (eg ornithine, citrulline, hydroxyproline, γ-carboxyglutamate, O-phosphoserine). Other covalent modifications that are considered include glycosylation, particularly N-glycosylation of one or more N residues.

In the context of the present invention, the first X residue (ie, the one closest to the amino terminus) may be referred to as X ₁ , the second X residue as X ₂ , the third residue as X _{3, and} so on.

In preferred embodiments, X ₁ is S, E, Q, H, P, or L.

In preferred embodiments, X ₂ is V, I, A, R, or F.

In preferred embodiments, X ₃ is S, T, H, L, or A.

In a preferred embodiment, X ₄ is N, Q or G.

In preferred embodiments, X ₅ is S, K, or T.

In preferred embodiments, X ₆ is H, R, or Q.

In preferred embodiments, X ₇ is I, L, F, or P.

Thus, examples of preferred amino acid sequences include:

Particularly preferred sequences are the sequences shown below, QLINTNGSWHI, QLVNTNGSWH
I, QLINNSNGSWHI, SLINTNGSWHI, ELINTNGSWHI, HL
Includes ANHQGKWRL, PLFNANGTWQF, and ELRNLGGTWRP.

In one embodiment, the peptide is substantially or essentially amino acid residue sequence XLXNX.
It consists of XGXWXX.

More preferably, the peptide has the formula:
X ₁ LX ₂ NX ₃ NGSWHI or X ₁ LX ₂ NX ₃ NGSWHIN
Contains an amino acid sequence that matches

This sequence is typically HCV E where only positions 412, 414 and 416 show natural mutations.
It matches the conserved sequence of amino acid residues 412 to 423 of 2 proteins. Preferably, X
₁ is Q, S or E. Preferably X ₂ is I or V. Preferably X ₃ is T or S.

In one embodiment, the peptide is substantially or essentially an amino acid residue sequence:
X ₁ LX ₂ NX ₃ NGSWIN
Consists of.

In another preferred embodiment, the peptide comprises additional amino acid residues. In particular, the peptide may comprise one or more additional B or T cell peptide epitopes. In particular, the peptide may comprise one or more additional T helper cell peptide epitopes.

Additional amino acid residues may include, for example, one or more repeats of the sequence XLXNXXGXWXX, and / or peptide epitopes from other parts of the HCV E2 glycoprotein, and / or completely from other HCV proteins or other It can include peptide epitopes from proteins. For example, the peptide has an amino acid residue sequence XLXNXXGXWXX of 1 or more B
Alternatively, it can be provided as part of a molecule that is covalently linked (but typically not necessarily by peptide bonds) to some other desired moiety, such as a peptide or polypeptide comprising a T cell epitope. Conveniently, such a molecule may be a fusion protein that can be expressed and synthesized in a biological system (eg, by a microorganism or by a tissue culture system). Peptide sequence repeats may optionally be separated by an intervening spacer or may be directly adjacent.

Alternatively, the epitope sequence can be provided as a branched molecule comprising multiple repeats of the epitope sequence. In one embodiment, the molecule comprises a C-terminal alanine residue linked to a branched core of lysine and multiple copies of the epitope.

If the epitope is present multiple times in the composition, the possibility of containing a mutated sequence arises, eg one peptide sequence can be a sequence where X ₁ is S and X ₂ is V, Another peptide sequence present may be a sequence in which X ₁ is Q and X ₂ is I.

In a further aspect, the invention provides a nucleic acid construct encoding a peptide having the amino acid residue sequence XLXXXXGXWXX, said peptide optionally comprising additional amino acid residues at the N and / or C terminus, said nucleic acid The construct does not encode the entire HCV E2 glycoprotein or its _E2660 fragment. The construct is typically an expression construct that includes a promoter so that the encoded peptide can be expressed in a suitable prokaryotic or eukaryotic host. Conveniently, the promoter is one that is operable in a mammalian host, particularly a human host. Many suitable promoters are known to those skilled in the art (eg, cauliflower mosaic virus (CaMV) promoter, rous sarcoma virus (RSV) promoter, dihydrofolate reductase (DHFR) promoter, retinoic acid receptor β)
(RAR-β) promoter, human cytomegalovirus immediate early gene 1 (HCMV) promoter, SV-40 promoter, human c-fos promoter).

In one particular embodiment, the nucleic acid construct encodes a peptide in which the amino acid sequence XLXNXXGXWXX is present multiple times as a contiguous repeat sequence or as a repeat sequence separated by an intervening spacer.

The construct may comprise one or more regulatory elements such as enhancers, an origin of replication, and one or more markers (
Selection or others). The construct may take the form of a plasmid, yeast artificial chromosome, yeast minichromosome, or may be integrated into all or part of the genome of a virus, particularly an attenuated virus or a similar virus that is non-pathogenic to humans.

The composition or construct is conveniently formulated for safe administration to a mammalian subject, preferably a human subject. Typically, they are provided in multiple aliquots, each aliquot containing a composition or construct sufficient for effective immunization of at least one healthy adult subject. If desired, compositions according to both the fourth and fifth aspects of the invention as defined above may be formulated.

The composition or construct may be provided in liquid or solid form, preferably as a lyophilized powder that is typically rehydrated with a sterile aqueous liquid prior to use.

Preferably, the composition or construct is formulated with an adjuvant or other component that has the effect of increasing the subject's immune response (eg, as measured by specific antibody titers) in response to administration of the composition or construct. The

An adjuvant is a substance that causes non-antigen specific stimulation of an immune response. Known adjuvants include cholera toxin (CT) and E. coli heat labile toxin (LT), its non-toxic B subunit and toxoid (ie, mutant molecules in which one or more mutations made them non-toxic or A and B sub Molecules made non-toxic by chemical treatment such as unit cross-linking)
Contains P-ribosylated bacterial toxins. Another known adjuvant is alum that has been approved for use in human vaccines. Other substances that can enhance the immune response include lipids, particularly lipid-containing vesicles, liposomes, micelles, and the like.

Administration of the construct to the subject results in the expression of a peptide epitope in at least a portion of the subject's cells, which in turn can induce an immune response against the epitope (ie, of B cells producing antibodies that bind to the epitope). Can induce population development and / or growth)
. Such constructs are commonly referred to as “DNA vaccines”. The nucleic acid may be administered to the host by any suitable route, eg, intravenous, subcutaneous route, or needle-free administration into or through the skin. Nucleic acids can be administered in “naked” form, or co-administered with other molecules, or with various types of particles, where the nucleic acid is encapsulated or bound to particles in some way. (Eg, bonded to a surface, typically by electrostatic attraction). Particles that can be used include liposomes, virus particles, gold microparticles, and the like. One viral particle that has been widely used for research in this general area is a modified vaccinia ankara virus (MVA) that can be used as a vector to deliver nucleic acids to host cells in a subject. M
VA has been recognized as safe so far. Other viruses that have been used as vectors include adenovirus and adeno-associated virus (AAV).

One skilled in the art need not administer the construct as DNA, but in fact can be administered as RNA as part of an RNA virus, which is then transcribed into DNA and then translated in the host cell. Recognize that.

The composition may be administered to the subject by any suitable route. Oral, nasal or other mucosal routes are non-invasive and are therefore preferred if they are found to be effective, but more routine routes such as intravenous, subcutaneous or intramuscular injection are It is likely to provoke a stronger immune response. The optimal dose of peptide to be administered can depend on the size and age of the subject, the route of administration, and the like. As a general guideline, an effective dose (ie, in a subject that has previously had no detectable antibody to the epitope, or that has some preexisting antibody titer in a subject that has had no detectable antibody titer). The dose that produces a detectable increase in antibody titer) is in the range of 50 μg to 500 mg for adults, preferably 100 μg to 2
Includes an amount of epitope within the range of 5 mg.

In one particular embodiment of the invention there is provided a composition according to the fourth aspect of the invention, further comprising a nucleic acid construct according to the fifth aspect of the invention.

Physiologically acceptable carriers, excipients or diluents can be solid or liquid. Suitable liquids include water and aqueous solutions such as saline, phosphate buffered saline and the like. Suitable solids include starch, dextran and gels (eg carrageenan, alginate, etc.).

The compositions and / or constructs of the invention may be used to induce antibodies in a subject that bind to HCV and neutralize the virus (ie, render it non-infectious). Regarding the present invention,
When the antibody is preincubated with the virus for 1 hour at 37 ° C. and the antibody has a concentration of 100 μg / ml or less, preferably 75 μg / ml or less,
An antibody can be considered neutralizing if it can cause at least a 50% reduction in the infectious titer of CV. Thus, the composition and / or construct can be
When encountering V, it can be used to generate antibodies that can prevent infection or at least provide limited protection by reducing the severity of the infection. Thus, the composition / construct can be used to completely prevent the disease or at least ameliorate the symptoms of infection.

Alternatively, the composition / construct can be used to enhance an immune response to HCV in a subject already infected with HCV, ie to treat a disease. Such treatment is
Virus cleaning from subjects with acute or chronic infection may be facilitated.

Accordingly, in a further aspect, the present invention comprises administering an effective amount of a composition and / or construct according to the present invention to elicit HCV neutralizing antibodies or enhance synthesis of HCV neutralizing antibodies in a subject. Methods of preventing and / or treating HCV infection in a mammalian subject, preferably a human subject, are provided. The dose and route of administration may conveniently be as described above.

As explained elsewhere, the inventors surprisingly found that the epitope XLXXNXX
It was found that antibodies that bind to GXWXX can neutralize viruses representing each known genotype of HCV. Thus, if such antibodies are present in a subject at sufficiently high concentrations, they should be able to protect against infection and / or disease caused by any genotype of HCV. One way to achieve a sufficiently high concentration of antibody is active immunization. An alternative approach is passive immunization, in which an existing antibody is administered to the subject.

Accordingly, in a further aspect, the present invention relates to epitope XLXNXXGXWXX 1
Provided is a method for preventing and / or treating HCV infection in a mammalian subject, preferably a human subject, comprising administering to the subject an effective amount of the above HCV neutralizing antibody. Such an antibody is conveniently a polypeptide according to the third aspect of the invention as defined above,
In particular, it may be a chimeric or, preferably, a humanized antibody or an antibody fragment comprising CDRs identical or substantially identical to that of AP33.

The antibody can be administered, for example, in the form of immune serum, or more preferably can be a purified recombinant or monoclonal antibody. Methods for producing serum or monoclonal antibodies with the desired specificity are routine and well known to those skilled in the art. The antibody may be administered by any suitable route, including but not limited to intravenous or intramuscular injection, intraperitoneal or transdermal route.

Preferably, the antibody administered is substantially purified (eg, preferably at least 95% homogeneity, more preferably at least 97, as determined by SDS-PAGE, for example).
% Uniformity, most preferably at least 98% uniformity). The antibody can be conveniently mixed or combined with pharmaceutically acceptable carriers, excipients or diluents, such as saline, phosphate buffered saline, Ringer's solution, dextrose solution, etc., optionally gelatin, Thickeners such as starch, alginate and derivatized cellulose can be included.

Passive immunization may conveniently involve administration of multiple antibodies having different specificities for HCV antigens and / or administration of antibodies in combination with other antiviral therapeutic compounds. Recently, such passive immunization techniques have been used safely to treat HIV infection (Armbr
uster et al, 2004 J. Am. Antimicrob. Chemother.
54, 915-920; Stiegler & Katinger 2003 J. Org. An
timmicrob. Chemother. 51,757-759).

The active or passive immunization method of the present invention is a very rare mutant isolate that contains several amino acid differences compared to the consensus peptide epitope defined above (UKN5 below).
. (As exemplified in 14.4) should allow protection or treatment of the individual against infection by any of the HCV genotypes 1-6 viruses.

In a further aspect, the present invention provides a diagnostic test apparatus and method, respectively, for detecting the presence of HCV. The device may include one or more antibodies that bind to the epitope XLXNXXGXWXX as reagents. The antibody is immobilized, for example, on a solid support (eg, on a microtiter assay plate or on a microparticle support), and HCV particles from a sample (eg, a blood or serum sample or other clinical specimen such as a liver biopsy). Can "capture" Captured viral particles can then be detected, for example, by adding additional labeling reagents that bind to the captured viral particles. Conveniently, the assay may take the form of an ELISA, in particular a sandwich type ELISA, but any other assay format may be employed in principle, including immunochromatographic or dipstick type assays (eg radioimmunoassay,
Western blot).

Antibodies that bind to XLXNXXGXWXX epitopes may be labeled or unlabeled. Any suitable label can be used, for example, a radioactive label, an enzyme label, a fluorescent label or a dye-loaded particulate label.

The assay method of the present invention involves the use of an antibody that binds to the epitope XLXNXXGXWXX.

Since antibodies can bind to HCV from any of genotypes 1-6, the assay device and corresponding method should be able to detect HCV representative of any of these genotypes in the sample.

In the last aspect, it is believed that a molecule comprising a peptide conforming to the general formula XLXNXXGXWXX can inhibit entry of HCV into sensitive cells by interfering with the fusion process.
Thus, for example, a peptide or polypeptide containing the above amino acid residue sequence is considered to have clinical utility, and therefore the present invention is mixed with a physiologically acceptable diluent, excipient or carrier. Pharmaceutical compositions containing such molecules are included. Such an approach is known as HIV
Recently described for the T20 peptide, corresponding to a portion of gp41 (Zwick et
al, 2004 Nature Medicine 10, 133-134).

To avoid doubt, unless otherwise indicated by context, the invention is herein "preferred", either alone or in combination with any other feature so described.
It is expressly stated herein that any feature expressed as “advantageous”, “advantageous”, etc. may be included. In addition, the contents of all publications mentioned in this specification are herein incorporated by reference.

  The invention will now be further described by way of illustrative examples.

C encoding E1E2 glycoprotein from patients infected with various genotypes of HCV
Isolation of DNA sequences is described in Lavillette et al. , (Reference 43). HCV pseudoparticles encapsulated with glycoproteins derived from various genotypes (HCV _pp
) To generate appropriate HCV E1E2 and murine leukemia virus (
A vector expressing MLV) Gag-Pol was used. We also utilized an MLV transduction vector encoding a GFP reporter protein that acts as a transduction marker.

HCV genotype 1a H full length E1E2 under the control of the human CMV promoter,
A plasmid expressing an MLV transfer vector carrying murine leukemia virus (MLV) Gag-Pol and GFP has been reported so far (Reference 6). CDNA sequence encoding HCV full-length E1E2 from various clinical isolates [HCV for H77c strain]
Amino acid residues 170-746 of the open reading frame are shown (ref. 70)]
Was created by PCR and cloned downstream from the human CMV promoter in the expression vector pCR3.1 (Invitrogen) or phCMV-7a (6) (ref. 6) and as described (43) their nucleotides The sequence was determined.

The experiment involved the use of cells from human embryonic kidney (HEK) 293T cells (ATCC CRL-1573) and human hepatocellular carcinoma (Huh-7). These are 10% fetal calf serum (FCS)
Grown in Dulbecco's modified Eagle's medium (DMEM, GBCO BRL) supplemented with 5% essential amino acids, glutamine and penicillin / streptomycin.

HCV _pp was made essentially as described previously (reference 6). Briefly, HEK293% cells were treated with calcium phosphate transfection (Sigma).
) Were cotransfected with a plasmid expressing MLV Gag-Pol packaging vector, MLV-GFP transduction construct, and HCV E1E2. In all experiments, an envelopeless control was used in which the HCV glycoprotein expression construct was excluded from the cotransfection of HEK293T cells. 2 days after transfection, HC
Medium containing V _pp was collected, clarified, filtered through a 0.45 μm pore size membrane and used for infection of Huh-7 cells. Four days after infection, cells were harvested and analyzed with a FACSCalibur (Beckton Dickinson) using CellQuest software. Transduction efficiency was determined as a percentage of GFP positive cells (typically 0.0
5%, after subtracting the number of GFP-positive Huh-7 cells “infected” in the no-envelope control). Infectious titers expressed as transduction units / ml were calculated from transduction efficiency.

The E1E2 sequence from an established infectious clone type 1a strain H (reference 6) was used as a control along with patient-derived E1E2 clones throughout this series of experiments. A total of 289 patient isolates were screened, of which 39 were able to render pseudoparticles infectious. Some of these properties were recently reported by the present inventors (Ref. 43
), Representative selection of these functional clones is shown in Table 1. At least one infectious clone representing each of the genotypes was identified. HCV _pp from some patient isolates was more reproducibly more infectious than that from the control genotype 1a H strain in this assay. For example, HCV _pp derived from the construct UKN2B1.1 typically transduced more than 30% of the target cells, but only 10-20% of those derived from H77. Typically, the infectious titre, expressed as transduction units / milliliter (TU / ml), is UKN2B
For 1.1, about 1 × 10 ⁵ TU / ml, for type 1a H line 4 × 10 ⁴ TU / ml
Met. In contrast, HCV _pp of genotypes 3, 5 and 6 gave very low titers ((
References 1-4) × 10 ³ TU / ml) (Table 1).

In order to examine why many of the isolates were not infectious, we
It was examined whether CV glycoprotein was expressed in transfected HEK293T cells. The relative levels of E2 glycoprotein in each cell lysate have been previously described for GNA (Galanthus nivalis) lectin-coated ELISA plates (Dynex Labsystems) and all for type 1a E2. (References 52 and 16) Measured by ELISA containing polyclonal rabbit serum R646 and two monoclonal antibodies (MAbs), AP33 and ALP98. M
Ab AP33 and R646 antisera were prepared according to the manufacturer's protocol (Amersha
m Biosciences) protein G column.

An ELISA assay to detect E2 glycoprotein was performed essentially as previously described (ref. 54). Briefly, E1E2 glycoproteins from clarified lysates of HEK293T cells co-transfected as described above were serially diluted 3-fold and captured on GNA lectin-coated ELISA plates. Conjugate glycoproteins using anti-E2 MAb AP33 or ALP98 or rabbit polyclonal serum R646, followed by anti-species IgG HRP (Sigma) and TMB (3,3 ′, 5,5′-tetramethyl-benzidine, Sigma) substrate Detected. Absorbance values were measured at 450 nm.

The results are shown in FIG. 1a, which is a series of graphs of absorbance (in arbitrary units) versus reciprocal dilution for various lysates tested. Results for AP33 detection are represented by black circles, ALP98 is represented by white circles, and R646 polyclonal antiserum is represented by black triangles.

HEK293T cell lysates co-transfected with each of the infectious clones with MLV Gag-Pol and GFP reporter constructs contain levels of E2 that give a strong, concentration-dependent signal for at least one of the two MAbs. It is. Type 4 isolate (U
KN4.2.16) and one of the two type 5 isolates tested (UKN 5.14.4)
Note that they were not recognized by MAb ALP98 and AP33, respectively. This is due to the presence of mutated amino acids within the epitope recognized by these antibodies (see below). Rabbit antiserum R646 is almost exclusively genotype 1a
H line E2 was recognized. That is, not only E2 from other genotypes but also E2 from different isolates of the same subtype (1A.14.36) could not be recognized.

Lysates of HEK cells transfected with all isolates that did not produce infectious HCV _pp were also analyzed by GNA ELISA for the presence of E2. Some had undetectable E2 or had low levels of E2, while others had E2 levels similar to those seen in lysates of cells transfected with infectious clones. Included (data not shown). We have lacked infectivity because some isolates do not express E2, and others are probably because the E2 or E1E2 complex they encode is in some way non-functional. It was concluded that it was non-infectious despite expressing high levels of E2.

The infectivity of HCV _pp depends on the integration of the full-length E1E2 complex into the particle envelope (Refs. 6, 39). The ELISA data confirmed the presence of E2 from various genotypes, but the presence of E1 could not be analyzed due to the lack of extensively reactive anti-E1 antibodies.
Instead, we examined the formation of the E1E2 complex by immunoprecipitation assay. HEK293T cells co-transfected with HCV glycoprotein expression constructs and MLV Gag-Pol and GFP transfer vectors were radiolabeled with [ ³⁵ S] methionine / cysteine.

  Radiolabeling was performed as follows.

18 hours after transfection, cells were washed with PBS and 25 μCi / ml L- [
³⁵ S] Redivue ™ Pro-Mix ™ (Amersham Biosc
incubation in methionine / cysteine-free medium containing
Transfected cell media was collected and clarified by centrifugation. Cells were washed with PBS and lysis buffer (20 mM Tris-HCl, pH 7.4, 20 mM iodoacetamide,
150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100)
The lysate was centrifuged briefly to remove nuclei. The medium containing the clarified cell lysate and HCV _pp was incubated with a mixture of anti-E2 MAb AP33 and ALP98 for 2 hours at 4 ° C., and the resulting immune complexes were precipitated using protein A-Sepharose. After washing the protein A-Sepharose beads, the immune complex was washed with SDS-PAGE denaturing buffer (2
00 mM Tris-HCl, pH 6.7; 0.5% SDS; 10% glycerol; 20 m
M DTT) and analyzed by SDS-10% PAGE. The gel is dried and exposed to a fluorescent screen overnight to remove the radiolabeled protein from Bio-Rad Personal.
Visualized with FX Phosphor imager.

  The result is shown in FIG.

E1 was co-immunoprecipitated with E2 from cell lysates transfected with the majority of glycoprotein expression constructs. There is some variation in the relative amount of protein produced,
Interesting differences were observed in the molecular weight of the precipitated proteins (especially E1). Since nucleotide sequence analysis shows variations in predicted glycosylation sites between various genotypes (ref. 43), these are probably due to differences in glycosylation. It should be noted that there was a significant variation in relative stoichiometry between various genotypes E1 and E2. Similarly, E1E2 complexes secreted into the media of transfected cells (some of which were expected to be in the form of HCV _pp ) were also detected by immunoprecipitation with the same MAb (data not shown) ).

(Neutralization of HCV _pp infected target cells with antibodies)
We tested the ability of MAb AP33, rabbit antiserum R645 and R646 (both raised against the soluble extracellular domain of type 1a H77c strain) to inhibit cellular H77c strain HCV _pp infection.

Antiserum R10 raised in New Zealand rabbits immunized with a branched peptide corresponding to the hypervariable HVR-1 region (residues 384-411) of genotype 1a H77c strain
20 and R1021 were also tested. The immunization protocol used to generate these antisera has been previously described (reference 53).

Neutralization assays were performed as follows. HCV with genotype 1a H strain E1E2
_pp , anti-E2 serum R645, R646, R1020 and R1021 or their pre-immune (
PI) Preincubation for 1 hour at 37 ° C. with a 1: 120 dilution of counterpart or MAb AP33 50 μg / ml. Next, Huh- plated on a 6-well tissue culture dish
The virus / antibody mixture was added to 7 cells and the cells were incubated at 37 ° C. for 3 hours. After removal of the inoculum, the cells were re-fed with fresh media and incubated at 37 ° C. for 4 days. The percentage of infected cells was determined by measuring GFP by FACS as described above. Neutralizing activity is defined as the antibody concentration required to achieve 50% or 90% inhibition of infection, respectively.
Expressed as IC ₅₀ or IC ₉₀ .

  The result is shown in FIG. 2A.

Of the rabbit antisera tested, R646 can completely eliminate infection, while R
645 blocked infection by about 50%. Both R1020 and R1021 anti-HVR1 antisera were able to neutralize infection by 65%. As expected, the corresponding preimmune rabbit sera did not affect HCV _pp infection. Like R646, MAb AP33 is H
Infection of Huh-7 cells by line 77c HCV _pp was completely blocked.

Next, we tested the ability of these antisera and MAb AP33 to neutralize HCV genotypes other than the 1a H77 strain. AP33 is widely cross-neutralizing, whereas antisera R645, R646 and R1020 have been found to have negligible effects on the infectivity of HCV _pp incorporating 1b, 2a or 2b glycoproteins. (FIG. 2b).
Since it has been established that R646 does not significantly inhibit infection by HCV _pp derived from genotypes other than 1a, we have determined whether its specificity is limited to glycoproteins of type 1a H strains. Or other type 1a isolates could be inhibited. As shown in FIG. 2c, this antiserum was isolated from two patient isolates 1A14.8 and 1A other than the 1a H line
It was not very effective against A14.36 and had an IC ₅₀ value of 200 ng IgG / ml.

The broad reactivity of MAb AP33 is attributed to an E derived from an isolate that represents the complete complement of the genotype.
Further investigation was performed by testing a series of concentrations on a panel of HCV _pp incorporating 1E2. As shown in FIG. 3, an isolated MAb AP33 representing all six genotypes.
HCV _pp with reactive E2 is from 0.6 μg / ml for genotype 5 to genotype 3
Effectively neutralized with an IC ₅₀ ranging up to 22 μg / ml for a. Genotype 5
The infectivity of one of the HCV _pp isolates, UKN 5.14.4, was not affected by MAb AP33 (data not shown), indicating that the E2 glycoprotein of this infectious isolate This is because it is not recognized by this antibody (FIG. 1A).

The amino acid sequence alignment (FIG. 4a) of the N-terminal region of E2 of the various genotypes used in this study shows that the MAb AP33 epitope (residues 412-423) has three mutant amino acid sites (residues 412, 414 and Only 416), indicating a relatively good preservation. Other sites within this epitope are absolutely conserved. An exception to this was the corresponding amino acid sequence in E2 encoded by the genotype 5 isolate UKN5.1.4.4. This is a potential glycosylation site (NG) compared to other isolates.
S) -1 shift and 4 residue changes in sequence (Figure 4a). In contrast, R646
The sequences corresponding to the linear epitopes of the genotype 1a H line recognized by, showed significant variation between different genotypes, consistent with its limited specificity. Finally, ALP
The epitope recognized by the 98 antibody (residues 644-651) was also conserved, but the arginine to valine mutation present at position 651 in the genotype 4 clone abolished recognition by this antibody (FIG. 4b). In order to examine in more detail the epitope recognized by AP33, the epitope was positioned in detail.

(Detailed mapping of AP33 contact residues using phage biopanning screen)
PhD (New E) of random peptide library (RPDL) displayed on phage
The ngland Biolabs [NEB]) series is based on the type 3 phage peptide display vector M13KE. Individual phage within these libraries express up to 5 copies of a random peptide fused to the N-terminus of the mature pIII capsid protein by the spacer sequence Gly-Gly-Gly-Ser. A library expressing random 12-mer peptides was used in our experiments (NEB catalog number E81).
10S). Affinity selection of the PhD phage-library was performed essentially as described by the manufacturer. Briefly, AP33 was incubated overnight at 4 ° C. with 100 μl of coating buffer (CB) (0.05 M carbonate-bicarbonate, pH 9.6) to obtain maxisorp microtiter plates (Nunc, Roskilde). ,
Denmark) wells were coated at a concentration of 10-100 μg / ml. After coating, the antibody solution is discarded, after which the wells are treated with 300 μl TBS-TB (0.1% (v / v) Tween 20 and 5% (w / v) milk powder (Marvel®, Cadbury's) In Tris-buffered saline, pH 7.6 [TBS]) for 1 hour. After discarding the blocking solution, the wells were washed 6 times with TBS-T (TBS with 0.1% (v / v) Tween 20) and then 1 × 10 × from PhD library diluted in 100 μl of TBS-T. ¹¹ phage were added. These phages were left at 25 ° C. for 1 hour to bind to immobilized AP33, and then unbound phages were removed through continuous washing with TBS-T. The bound phage is eluted with 100 μl 0.2 M glycine-HCl (pH 2.2) for 10 minutes, transferred to a microcentrifuge tube and then 15 μl 1 M Tris-HCl (pH 9.1).
Neutralized by the addition of

Recovered phage were titrated by preparing serial dilutions of eluted phage in LB, and 10.0 μl of each diluted solution was added to logarithmic growth phase (0.3 OD _{600 nm} ) E. coli ER2
It added to 250 microliters of 537 strains (NEB). After infecting the bacteria with the phage for 5 minutes at 25 ° C., the bacteria were mixed with 3 ml of 0.7% agar containing 1 mM X-Gal and 1 mM IPTG and overlaid on LB agar plates. Allow the agar to solidify for 5 minutes, then turn the plate over and place 37
Incubate overnight at ° C. Subsequently, the titer of the phage was calculated from the average number of blue plaques formed using the equation: phage μl ⁻¹ = ([average number of blue plaques] × [dilution] ⁻¹ ) / 10.

The enhanced phage library was then propagated by adding 50 μl of eluted phage (approximately 1 × 10 ⁵ PFU) to 20 ml of log phase E. coli ER2537 strain in LB and incubating at 37 ° C. for at least 4 and a half hours. After phage growth, bacteria and other debris were removed by centrifugation at 10,000 xg for 10 minutes (Sorvall SS-34).
1/5 volume of PEG (20% [w / v] polyethylene glycol-8000, 2.5M
Sodium chloride) was added at 4 ° C. for 1 hour to precipitate phage from the supernatant of this culture.
Collected by centrifugation at 5,000 xg for 20 minutes. Next, the phage pellet is TBS.
After resuspension in 1.0 ml, a second precipitation was performed with 1/5 volume of PEG for 1 hour on ice. Centrifuge for 20 minutes at 10,000 xg (MSE Micro Cent
aur) and the phages were collected and resuspended in a final volume of 200 μl of sterile TBS. The concentration of phage in the expanded library was determined by titration as described above, and then 1
X10 ¹² phage was used as input to a further 2-3 affinity selections.

After the final round of affinity selection, individual plaques obtained from titration of eluted phage are
Using a sterile pipette tip, 2 ml of log phase culture of ER2537 was inoculated and grown at 37 ° C. for 4 and a half hours. The phage is recovered from the supernatant of this culture by two rounds of precipitation as described above,
Resuspended in 100 μl TBS. The phage stock solution was stored at -20 ° C.

Enzyme-linked immunosorbent assay (EIA) was used to examine the antigenicity of peptides concentrated from 12-base untreated RPDL. AP33 diluted to 1.0-100 μg / ml in 50 μl of CB was coated directly onto the wells of a microtiter plate by overnight incubation at 4 ° C. After blocking (as described above), approximately 1 × 10 ¹¹ phage particles were added to the wells and allowed to bind for 1-2 hours. Thereafter, anti-fd diluted 1: 1000 in TBS-T.
Bound phage was detected by incubation with (Sigma, catalog number B-7786). The binding of these antibodies was then detected by sequential incubation with alkaline phosphatase conjugated to anti-rabbit secondary antibody and pNPP substrate (Sigma) and the OD was read at 490 nm.

The sequencing template DNA is the primer gIII (f) 5′-ATTCCTTTTAGTGG
TACCTTTTC-3 ′ was prepared by PCR amplification of DNA from approximately 1 × 10 ⁹ phage using with the -96 sequencing primer supplied by the manufacturer. Standard polymerase chain reaction (PCR) was used for amplification of DNA from both phage particles and bacteria. For each reaction, 10 × PCR buffer (100 mM Tris-HCl, 15
mM MgCl ₂ , 500 mM KCl [pH 8.3]) 2.5 μl, each primer 5.0 μl (5.0 pmol), HotStar Taq polymerase (Qiagen)
0.1 μl (0.5 units) and 10.0 mM dNTP mixture (2.5 mM dATP,
0.5 μl (containing dCTP, dGTP and dTTP) was added to the thin-walled microcentrifuge tube. After making the reaction volume 25.0 μl with DNase / RNase-free water, 1.0 μl of phage particles diluted to about 1 × 10 ⁹ phage / ml with DNA-free water was added. Next PT
DNA was amplified by PCR cycling (35 cycles of 95 ° C, 45 seconds, 50 ° C, 45 seconds, 72 ° C, 90 seconds) on a C-100 / 200 thermal cycler (MJ Research).

After amplification, unincorporated nucleotides and oligonucleotides are
Shrimp alkaline phosphatase (SAP) and exonuclease I (Exo I) each 1
. 0 μl was added and then removed by incubating at 37 ° C. for 30 minutes. SAP and Exo I enzymes are then inactivated at 75 ° C. for 15 minutes and 5.0 μl of SAP / Ex
o Template DNA from I-treated PCR product was transferred to BigDye in a thin-walled PCR tube.
terminator ready reaction mix (Applied Bi
ossystems) 4.0 μl and -96 sequencing primer 1.0 μl (1 pmol)
And a cycle sequence method (25 cycles of 96 ° C., 10 seconds, 50 ° C., 5 seconds, 60 ° C., 4 minutes) was performed using a Perkin-Elmer 9600 thermal cycler. Next, 10.0 μl of DNase-free water and 3 M sodium acetate (pH 5.2) 2
. After adding 0 μl (0.1 volume) to the tube, it was centrifuged briefly and transferred to a sterile microcentrifuge tube. The sequenced DNA was then precipitated by the addition of 45.0 μl of 100% ethanol and incubation at 25 ° C. for 10 minutes. Precipitated DNA is 1
The mixture was collected by centrifugation at 5,000 × g for 20 minutes, washed with 45.0 μl of 70% ethanol, and dried at 37 ° C. for 15 minutes. Subsequently, sequence analysis was performed using an ABI Prism 310 gene analyzer.

Identification of conserved residues of the EIA-responsive enhanced presentation peptides that are likely to form contacts with the AP33 paratope was performed by computer-assisted alignment of putative peptides.

After 3 selective biopannings against immobilized AP33, 22 phage clones were picked, expanded and their reactivity against AP33 antibody was measured by EIA (FIG. 5). FIG. 5 shows that the peptides displayed by the majority of enhanced phage interact specifically with the AP33 antibody. The specificity of the interaction is confirmed by the lack of reactivity to the control ALP98 antibody.

In order to identify the residues most likely to be involved in mediating the binding of the peptides to AP33 peptides, DNA sequencing of the selected peptides was performed and their predicted amino acid sequences were determined using computer-aided alignment. Aligned. Three groups of phage were identified, each group containing a unique peptide sequence (Figure 6). Their consensus sequence is
Along with the alignment of each group to the predicted AP33 epitope, indicates that a critically important binding motif can be defined as XLXNXXGXWXX.

In FIG. 6, panel A shows the deduced amino acid sequence of the random peptide insert present in the phage selected by antibody AP33. The deduced amino acid sequence (panel B) present in each of the selected phage peptides of the reaction group aligned against the putative AP33 epitope is:
Identify conserved contact residues involved in antibody-epitope interactions. Clone P3
. It should be noted that 5 is non-reactive in AP33 EIA (FIG. 5) and this peptide shows very little complementarity to the AP33 epitope.

Detailed mapping of AP33 and 3/11 epitopes using alanine substitution mutant E1E2 protein
The findings described in Example 5 above were further enhanced by experiments with a panel of H77 E1E2 mutant clones in which one residue was replaced with alanine at every position within the putative AP33 epitope. This panel has also been described to bind to the same epitope (Flint et al, 1999 J. Virol. 73, 6235-624).
4) It was also used to study the binding of rat monoclonal antibody 3/11. 3/11
And AP33 were both purified from the hybridoma supernatant using a protein G column.

Various E1E2 mutants were expressed in HEK293T cells, and the reactivity of the resulting protein to MAbs AP33 and 3/11 was evaluated using GNA-captured EIA (FIG. 9). AP for mutants L413A, N415A, G418A and W420A
33 binding was reduced by more than 75% compared to the wild type, indicating that these residues are very important for binding. Mutants T416A and N417A also reduced AP33 binding, but this effect was not as pronounced as for the other four mutants. 4
Replacement of glutamine with alanine at position 12 (Q412A) consistently enhanced the binding of AP33 to E1E2, increasing it by approximately 50% compared to the wild type H77 protein. In contrast, this substitution had no effect on MAb 3/11 binding. The remaining 5 residue alanine substitutions had negligible effects on AP33 recognition.

A consistent and significant decrease in binding by MAb 3/11 compared to the wild type H77 protein was observed for mutant N415A, W420A and H421A, and MAb 3 /
The importance of these residues in binding by 11 was highlighted (data omitted for brevity). Substitution of isoleucine at position 422 resulted in a moderate enhancement of 3/11 binding.
Alanine substitution of the remaining residues had no effect or caused moderate loss of binding compared to wild type.

(Comparison of binding affinity and HCV _pp neutralization efficiency of MAb AP33 and MAb 3/11)
Since detailed epitope mapping experiments suggested that MAbs AP33 and 3/11 recognize different contact residues within the E2 protein, we have found that these differences are binding affinity or neutralizing potency. We proceeded to evaluate whether it could be translated into the difference. 4
The concentration of MAb AP33 required to obtain 50% binding to the 12-423 branched peptide was more than 10 lower than that required for MAb 3/11 (FIG. 10: AP33).
= Circle, 3/11 = triangle). Similarly, in the biotinylated MAb binding assay, AP33
Was more efficient than 3/11 in competition for binding (data not shown).
Compared to MAb 3/11, competition by MAb AP33 is similar to biotinylated MAb A.
It produced a greater reduction in binding by both P33 and 3/11. The MAb also showed a significant difference in affinity for E1E2 representing various HCV genotypes (FIG. 11).
The concentration of MAb AP33 required to obtain 50% binding to E1E2 protein is approximately 1 ×
Ranged from 10 ¹ to 1 × 10 ³ ng / ml, while about 1 × 10 ² to 1 × 10 ⁴ ng / ml
50% binding was achievable using 3/11 concentrations in the range. Taken together, these data indicate that AP33 has a higher affinity for E2 than MAb 3/11.

Similarly, MAb A neutralizing HCV _pp carrying E1E2 representing genotypes 1-6
A comparison of P33 and 3/11 capacity (FIG. 12) shows that both antibodies have broad neutralizing capacity, but A
The neutralizing potency of P33 was consistently higher than MAb 3/11 (p <0.001, Wilcoxon matched pair test). MAb AP3 when used at a concentration of 50 μg / ml
3 was able to neutralize the infectivity of HCV _pp by 80-99%. In contrast, MAb 3 /
The same concentration of 11 produced only 10-80% neutralization. As described herein, MA
b AP33 carries HCV _pp carrying E1E2 from UKN 5.14.4 strain of genotype 5
Was hardly neutralized. Similarly, MAb 3/11 could not neutralize HCV _pp carrying this E1E2 clone. This isolate has a 4 amino acid change (QLIQNGSSSWIN) in the E2 region corresponding to residues 412-423. This mutation
Two of the residues important for AP33 recognition (N415 and G418) and one important for 3/11 (N415) are changed. Both MAb AP33 and 3/11
Unable to react with UKN5.15.4 E2. Thus, not surprisingly, both MAbs are also unable to neutralize UKN 5.14.4 HCV _pp .

(Sequence analysis of _VH and _VL regions of AP33 and 3/11)
MRNA from approximately 10 ⁶ hybridoma cells was RNe according to the manufacturer's protocol.
Isolated using an asy mini kit (Qiagen). Add 4 μl of total RNA with Thermoscript (In) along with the poly-dT oligonucleotide primer included in the kit.
Reverse transcription using Vitrogen, UK). The resulting 2 μl of cDNA was used as a template in PCR designed to amplify the light and heavy chain variable regions.

Amplification of the heavy chain was performed using the sense primer VH1BACK (5′-AGG TSM ARC
TGC AGS AGT CWG G-3 ') and antisense primer VH1FoR-
2 (5'-GGG GCC AAG GGA CCA CGG TCA CCG TC
TCCT CA-3 ′) and HotStar Taq (Qiagen) as previously described (McCafferty & Johnson: Constru
ction and Screening of Antibody Display
Libraries. In: “Page Display of Peptides
and Proteins: A Laboratory Manual ". Ed. Ka
y et al 1996, p79-111). Light chain amplification is performed using primer Mk
(5′-GGG AGC TCG AYA TTG TGM TSA CMC ARW
CTA MCA-3 ′) and reverse primer Kc (5′-GGT GCA TGC GGA)
(Wang et al, 2000 J. Immunol. Methods 2) as previously described using TAC AGT TGG TGC AGC ATC-3 ′).
33, 167-177). The PCR product is column purified using a Qiaquick PCR purification kit (Qiagen) and then cloned into the Promega pGEM®-T vector using the pGEM®-T vector system according to the manufacturer's recommendations. did. Two clones for each heavy and light chain were identified as T7 positive primer and M
13 reverse primer (Promega) and ABI PRISM BigDye Term
inator Cycle Sequencing Ready Reaction K
It was sequenced using it (Perkin Elmer Applied Biosystems) according to the manufacturer's protocol. The nucleotide sequence determined for AP33 is shown in FIG.

(result)
The deduced amino acid sequences corresponding to the light and heavy chain variable regions of MAb AP33 and 3/11 were compared. The most striking feature of this comparison is that the heavy chain CDR3 for MAb AP33 is 10
Of mainly hydrophobic amino acids. In contrast, the heavy chain CDR3 of MAb 3/11 contained only 3 amino acids. IgBLAST search is based on MAb AP33
Heavy and light chains of mouse VH-36-60, subgroup VH-I (accession number K
01569) and VK-21-10 (accession number K02160). Germline analysis of 3/11 sequences was not possible due to the small number of rat germline sequences available in the Genbank database.

(HCV neutralization)
This example demonstrates that AP33 can neutralize HCV virus.

Production of chimeric HCV J6-JFH1 genomic cDNA. Plasmid pJFH1 carrying the full length HCV genotype 2a JFH1 strain cDNA downstream of the T7 RNA polymerase promoter is Wakita (Wakita et al., 2005 Nat
ure Medicine 11, 791-796).
To create a chimeric construct, NS2 core of the JFH1 strain cDNA, E1, E2, p7
And the nucleotide sequence coding for the N-terminal portion of another genotype 2a J6CF
Substitution with nucleotide sequences from the strain (Yanagi et al., 1999 Vi)
rology 262, 250-263). The resulting chimera J6-JF, called J71
Infectious virus generated from the H1 construct was used in the virus neutralization assay described below.

(HCV J71 RNA transfection and virus production in cell culture)
The J71 construct was linearized by cleavage at a restriction enzyme site located immediately after the 3 ′ end of the viral genomic cDNA. HCV J71 RNA was converted to MEGAscript High
Yield transcription kit (Ambion) was transcribed in vitro from the linearized construct using as described by the manufacturer. About 10 μg of in vitro synthesized J71 RNA was added to a 0.4 cm Gene Pulser cuvette (
Bio-Rad) mixed with Huh-7 cells and GenePulser Xcell
Pulsed once at 960 μF, 270 V using a (Bio-Rad) electroporation apparatus. Transfected cells were immediately mixed with cell culture medium and inoculated into 80 cm ² flasks and coverslips. After 4 days incubation at 37 ° C., the medium from the flask is collected,
Clarified by brief centrifugation to remove cell debris, filtered through a 0.45 μm pore size membrane and used to infect naïve Huh-7 cells. After 4 days incubation at 37 ° C., the infected cells were found to contain viral antigens that confirmed the presence of infectious viral progeny in the media collected from the electroporated cells. Electroporated cells on the cover glass were fixed and the presence of viral proteins was determined by indirect immunofluorescence.

It was observed that when the electroporated cells were passaged so that the majority of the cells contained the replicating viral genome until passage 7, the number of virus antigen positive cells increased.

(HCV neutralization assay)
Cell culture-produced HCV J71 virus was collected from the culture medium of passage 10 viral RNA-transfected Huh-7 cells, clarified, filtered as described above, and used in a virus neutralization assay as described below. . 200, 40, medium containing virus
Mixed with 8, 1.6, 0.32, 0.064 μg / ml of purified MAb AP33 or 3/11 and incubated at 37 ° C. for 1 hour. Then each of the virus - antibody mixture, 10 ^-1
In the range of -10 ⁻⁷ , serial dilution was 10-fold in complete medium. Each dilution was used to infect Huh-7 cells in a 48-well tissue culture dish (6 wells for each dilution) and after incubating the cells for 3 hours at 37 ° C., the inoculum was removed, Cells were re-fed with fresh media and incubated at 37 ° C. for 4 days. Cells were then washed once with PBS, fixed with methanol, and sheep anti-NS5a antiserum (Mark Harris, University o).
f) provided by courtesy of Leeds) was used to probe virus NS5a and anti-sheep IgG-FITC complex (Molecular Probe) was used to detect the bound antibody. Holes are recorded for the presence or absence of fluorescent cells and the infectivity of the virus is essentially determined by Lindenbach et al (2005) Science 309, 623.
Measured as TCID ₅₀ (tissue culture infectious dose) as described by 626.

(Discussion)
Previous tests have measured the neutralizing ability of sera or antibodies against only a very limited range of HCV genotypes (5, 21, 30). We used the HCV _pp assay to evaluate the ability of a series of E2-specific antibodies and sera to neutralize HCV _pp carrying E1E2 representing all major genotypes 1-6.

Having established a panel of functional E1E2 clones representing all major genotypes, we have raised rabbit antisera raised against either the HVR1 region or the extracellular portion of the E2 protein of MAb AP33 and H77c strains. We proceeded to evaluate the ability of HCV _pp to neutralize invasion. Both rabbit antisera raised against the HVR1 and extracellular domains of E2 were able to neutralize HCV _pp incorporating H77c E1E2, but neutralization between rabbits immunized with the same immunogen The difference in efficacy was obvious. However, both showed low neutralization of HCV _pp incorporating heterologous genotype 1a E1E2, and did not neutralize HCV _pp containing E1E2 from other genotypes tested. The high genetic diversity of HVR1 explains the low cross-neutralization observed, and this finding is consistent with previous reports of the limited neutralizing capacity of native HVR1-specific antibodies (76). Rabbit immunization with the E2 extracellular domain also resulted in the induction of neutralizing antibodies, but again these responses were highly strain specific. Peptide mapping and competition assays showed that the most potent neutralizing serum (R646) recognizes both conformational and linear determinants. Neutralization can be inhibited by natural but denatured sE2, suggesting that neutralizing antibodies are likely to recognize conformational epitopes.

Previous studies have shown that antibodies elicited after immunization with HCV envelope glycoproteins can at least partially protect against allogeneic challenge (33, 59). Similarly, many widely neutralizing human monoclonal antibodies have been described, all of which recognize conformational epitopes (1, 9, 37, 38, 40, 42). These antibodies are
It may have a future role in the treatment of HCV infection. They will also help to define future vaccine candidates. However, studies with HIV-1 have shown that focusing the immune response on epitopes recognized by a broad range of neutralizing antibodies is an important challenge. In this regard, the finding that AP33 strongly neutralizes the invasion of HCV _pp carrying a very diverse E1E2 is important because its epitope is linear and highly conserved across various genotypes of HCV It is. The epitope recognized by AP33 is located at residues 412-423 (demonstrated by the sequence QLINTNGSWHIN) and carries one potential N-linked glycosylation site (52). HCV _pp from one genotype 5 isolate (UKN 5.14.4) is infectious but MAb AP
It is interesting to note that it was not recognized by 33 (and therefore was not neutralized). This isolate had a well-conserved N-linked glycosylation site shifted -1 compared to the other isolates and a 4 amino acid change in the E2 region corresponding to the AP33 epitope ( QLIQNGSSWHIN). Subsequent analysis of the sequences deposited in the Genbank database showed that the AP33 epitope is highly conserved. The average sequence diversity compared to the original AP33 epitope was 4.7%, and the majority of the variable amino acids were located at the N-terminus of the predicted epitope. Importantly, a sequence similar to that present in UKN 5.14.4 was not apparent. Our preliminary data show that one of the four variant amino acids returned to its conserved counterpart (ie Q to N) was UKN 5.14.4.
Makes HCV _pp non-infectious (remains non-reactive with MAb AP33) (not shown), thus highlighting the potential importance of this region of E2 in infection. This finding suggests that UKN 5.14.4 HCV _pp infectivity of N415Q and N-linked glycosylation sequences
Together with the fact that it is not affected by one shift, it is suggested that this particular isolate may represent a neutralization avoidance mutant.

In conclusion, the inventors have shown that the epitope defined by the AP33 antibody is highly conserved across all major genotypes and that this antibody has a broad neutralizing capacity.

(References)

All publications mentioned in the above specification are hereby incorporated by reference. Various modifications and variations of the described method and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the invention has been described with reference to certain preferred embodiments, it is to be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Shows various ELISA results and shows a series of graphs of absorbance (arbitrary units) versus dilution factor. FIG. 6 shows SDS-PAGE analysis of radiolabeled polypeptides immunoprecipitated with a mixture of anti-E2 MAb AP33 and ALP98. The numbers on the left indicate molecular weight markers. Shown are bar graphs showing the degree of neutralization of HCV genotype 1 pseudoparticles by various antisera and pre-immune control sera (“PI” suffix) or MAb AP33. The vertical axis represents the ratio (%) of fluorescent cells (infected cells). FIG. 6 is a graph showing the degree of neutralization of genotypes 1A, 1B, 2A and 2B HCV _pp by various antisera or MAb AP33. It is a graph which shows the relationship between the density | concentration about antiserum R646 with respect to genotype 1A HCV subtype, and neutralization. FIG. 6 is a graph showing the relationship between MAb AP33 concentration and neutralization for various HCV genotypes. A portion of the amino acid sequence of the E2 protein of various HCV monopotents representing each of the six known genotypes is shown. A portion of the amino acid sequence of the E2 protein of various HCV monopotents representing each of the six known genotypes is shown. FIG. 5 is a bar graph showing the reactivity of antibodies AP33 (white bars) and ALP98 (black bars) with various selected phages in an EIA assay. The deduced amino acid sequence of the peptides expressed by the various phage clones (panel A) and alignment with the corresponding portion of the HCV H77 E2 protein (panel B) is shown. The nucleotide sequence derived by the present inventors from the hybridoma encoding the light chain and heavy chain variable regions of the AP33 monoclonal antibody is shown (primer determination sequences are omitted). The DNA sequence obtained from the cDNA cloned from the AP33 hybridoma (lower DNA sequence) and the primer DNA sequence used (upper) for the light chain and heavy chain variable regions are shown. The deduced amino acid sequence is shown above the DNA sequence. The amino acid sequence group constituting the CDR is underlined. An additional residue (“X”) is thought to be present at the start of framework region 1 of the heavy chain. FIG. 5 is a bar graph showing the amount of AP33 binding to various alanine-containing mutant forms of the E1E2 protein as determined by EIA compared to binding to the wild type E1E2 sequence. It is a graph which shows the relationship between the antibody concentration and the ratio (%) of the binding which compared the coupling | bonding of AP33 (circle symbol) and 3/11 (triangle symbol) to related peptide. FIG. 6 is a series of graphs showing the relationship between antibody concentration (ng / ml) and percent binding (%) for AP33 (circles) and 3/11 (triangles) when binding to various HCV genotype E1E2 proteins. FIG. 5 is a bar graph showing the infectivity percentage for various HCV _pp clones representing various HCV genotypes when exposed to AP33 (black bars) or 3/11 (white bars) at a final concentration of 50 μg / ml. It is a graph which shows neutralization of HCV J71 by AP33 (black circle) and 3/11 (white circle) monoclonal antibodies. Irrelevant monoclonal antibody DB165 (black triangle) and no antibody (white triangle) are shown as controls.

Claims (37)

A method of using a ligand capable of binding to an epitope of HCV E2 polypeptide defined by monoclonal antibody AP33 in the manufacture of a composition for the prevention or treatment of infection by HCV of each of genotypes 1-6. Said ligand, use of SEQ _{X 1 LX 2 NX 3 X 4} GX 5 WX 6 X 7 claim ₁ (X 1 ~ ₇ is an amino acid) is capable of binding to a polypeptide epitope with Method. The method according to claim 2, wherein X ₁ is selected from the group consisting of S, E, Q, H, P and L. The method according to claim 2, wherein X ₂ is selected from the group consisting of V, I, A, R and F. The method according to claim 2, wherein X ₃ is selected from the group consisting of S, T, H, L, or A. The method according to claim 2, wherein X ₄ is selected from the group consisting of N, Q or G. The method according to claim 2, wherein X ₅ is selected from the group consisting of S, K or T. The method according to claim 2, wherein X ₆ is selected from the group consisting of H, r or Q. The method according to claim 2, wherein X ₇ is selected from the group consisting of I, L, F or P. The polypeptide epitope is QLINTNGSWHI, QLVNTNGSWHI,
QLINSNGSWHI, SLINTNGSWHI, ELINTNGSWHI, HLAN
The method according to claim 2, wherein the method is selected from the group consisting of HQGKWRL, PLFNANGTWQF and ELRNLGGTWRP.   The method according to claim 1, wherein the ligand is an immunoglobulin. _{2. The} immunoglobulin fragment is an immunoglobulin fragment selected from the group consisting of Fab, F (ab ′) ₂ , Fv, scFv and single domain antibody (dAb) molecules.
The method of using according to 1. The method according to claim 11 or 12, wherein the ligand comprises one or more CDRs derived from the monoclonal antibody AP33. The one or more CDRs are
(A) RASESVDGYGNSFLH, LASNNLNS, QQNNVDPWT, GD
An array consisting of SITSGYWN, YISSYSGSTY or ITTTTYAMDY,
(B) a sequence in which 1, 2 or 3 amino acids are added, substituted or deleted from the sequence shown in (a), and (c) when the CDR is present in an immunoglobulin, the sequence shown in (a) 14. Use according to claim 13, selected from the group consisting of structurally similar sequences. The method according to any one of claims 11 to 14, wherein the immunoglobulin is humanized, thinned, resurfaced, CDR transplanted, SDR transferred or deimmunized immunoglobulin. The use according to any one of claims 1 to 15 for the prevention of vertebrate cell infection by HCV. A method for the prevention or treatment of infection by two or more HCV which is any of genotypes 1-6, comprising administering an effective amount of a ligand according to any one of claims 1-16. Including methods. A method for the prevention or treatment of infection by two or more HCVs of any of genotypes 1 to 6, comprising administering an effective amount of the immunoglobulin according to any one of claims 11 to 16. Including methods. An immunoglobulin molecule that neutralizes HCV isolates belonging to two or more HCV that are any of genotypes 1-6, wherein said immunoglobulin comprises one or more CDRs derived from monoclonal antibody AP33, An immunoglobulin molecule other than the monoclonal antibody AP33. The one or more CDRs are
(A) RASESVDGYGNSFLH, LASNNLNS, QQNNVDPWT, GD
An array consisting of SITSGYWN, YISSYSGSTY or ITTTTYAMDY,
(B) a sequence in which 1, 2 or 3 amino acids are added, substituted or deleted from the sequence shown in (a), and (c) when the CDR is present in an immunoglobulin, the sequence shown in (a) 20. The immunoglobulin molecule according to claim 19 selected from the group consisting of structurally similar sequences. An immunoglobulin molecule that neutralizes HCV isolates belonging to two or more HCV of any of genotypes 1-6, wherein said immunoglobulin molecule has the sequence X ₁ LX ₂ NX ₃ X ₄ GX ₅ WX ₆ X
₇ (X ₁ ~ ₇ is an amino acid) are those which are capable of binding to a polypeptide epitope with, the immunoglobulin is other than monoclonal antibody AP33, immunoglobulin molecules. 22. An immunoglobulin molecule according to any one of claims 19 to 21 comprising one or more human framework regions. 23. The immunoglobulin according to any one of claims 19 to 22, which is a humanized, thinned, resurfaced, CDR grafted, SDR transferred or deimmunized immunoglobulin. 24. The immunoglobulin according to any one of claims 19 to 23 comprising one or more human CDRs. A polynucleotide encoding the polypeptide according to any one of claims 19 to 24. A composition for inducing an antibody that binds to hepatitis C virus (HCV) E2 glycoprotein, said composition comprising a peptide having the amino acid residue sequence XLXNXXGXWXX and a physiologically acceptable carrier, excipient or A diluent, said peptide optionally comprising additional amino acid residues at the N and / or C terminus, but the entire HCV E2 glycoprotein or its E2 ₆₆₀ fragment (ie residues 384-660 of the HCV polyprotein) Wherein one or more of the amino acid residues may be covalently modified. The peptide has the amino acid sequence X ₁ LX ₂ NX ₃ X ₄ GX ₅ WX ₆ X ₇ (X ₁ is S, E, Q, H
, P and L, X ₂ is selected from the group consisting of V, I, A, R and F, X ₃ is selected from the group consisting of S, T, H, L and A, X ₄ is selected from the group consisting of N, Q and G, X ₅ is selected from the group consisting of S, K and T, X ₆ is selected from the group consisting of H, r and Q, and X ₇ is I, 27. The composition of claim 26, comprising: selected from the group consisting of L, F and P. The peptide is QLINTNGSWHI, QLVNTNGSWHI, QLINSNG
SWHI, SLINTNGSWHI, ELINTNGSWHI, HLANHQGKWRL
28. The composition of claim 27, comprising an amino acid sequence selected from the group consisting of: PLFNANGTWQF and ELRNLGGTWRP. 29. The composition according to any one of claims 25 to 28, wherein the peptide additionally comprises a T cell epitope and / or further a B cell epitope. 30. The composition of any one of claims 25 to 29, wherein the peptide comprises one or more repeats of amino acid residue sequences that match the general sequence XLXNXXGXWXX. 31. The composition of claim 30, wherein the peptide comprises two or more non-identical amino acid residue sequences that match the sequence XLXNXXGXWXX. 32. The composition according to any one of claims 25 to 31, wherein the peptide is present as part of a fusion protein.   33. The composition according to any one of claims 25 to 32, wherein the composition comprises a branched peptide.   34. The composition of any one of claims 25 to 33, further comprising an adjuvant. 34. A nucleic acid construct encoding a peptide used in the composition according to any one of claims 25-33. A kit for detecting the presence of HCV belonging to two or more HCVs of any of genotypes 1 to 6, comprising an immunoglobulin containing one or more CDRs derived from monoclonal antibody AP33. The one or more CDRs are
(A) RASESVDGYGNSFLH, LASNNLNS, QQNNVDPWT, GD
An array consisting of SITSGYWN, YISSYSGSTY or ITTTTYAMDY,
(B) a sequence in which 1, 2 or 3 amino acids are added, substituted or deleted from the sequence shown in (a), and (c) when the CDR is present in an immunoglobulin, the sequence and structure shown in (a) 37. The kit of claim 36, wherein the kit is selected from the group consisting of substantially similar sequences.

Images